<SEC-DOCUMENT>0001140361-22-021148.txt : 20220531
<SEC-HEADER>0001140361-22-021148.hdr.sgml : 20220531
<ACCEPTANCE-DATETIME>20220531073029
ACCESSION NUMBER:		0001140361-22-021148
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		16
CONFORMED PERIOD OF REPORT:	20220509
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20220531
DATE AS OF CHANGE:		20220531

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Brooklyn ImmunoTherapeutics, Inc.
		CENTRAL INDEX KEY:			0000748592
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				311103425
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-11460
		FILM NUMBER:		22980474

	BUSINESS ADDRESS:	
		STREET 1:		140 58TH STREET, BUILDING A
		STREET 2:		SUITE 2100
		CITY:			BROOKLYN
		STATE:			NY
		ZIP:			11220
		BUSINESS PHONE:		(212) 582-1199

	MAIL ADDRESS:	
		STREET 1:		140 58TH STREET, BUILDING A
		STREET 2:		SUITE 2100
		CITY:			BROOKLYN
		STATE:			NY
		ZIP:			11220

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NTN BUZZTIME INC
		DATE OF NAME CHANGE:	20051230

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NTN COMMUNICATIONS INC
		DATE OF NAME CHANGE:	19920703

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ALROY INDUSTRIES INC
		DATE OF NAME CHANGE:	19850411
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>brhc10038309_8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:currency="http://xbrl.sec.gov/currency/2021" xmlns:naics="http://xbrl.sec.gov/naics/2021" xmlns:sic="http://xbrl.sec.gov/sic/2021" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:exch="http://xbrl.sec.gov/exch/2021" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:btx="http://brooklynitx.com/20220509" xmlns="http://www.w3.org/1999/xhtml">
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, Inc
         Document created using EDGARfilings PROfile 8.2.0.0
         Copyright 1995 - 2022 Broadridge -->
    <meta http-equiv="Content-Type" content="text/html" />
</head>

<body style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; background-color: #ffffff;">
<div id="DSPFiXBRLHidden" style="display: none;"><ix:header><ix:hidden><ix:nonNumeric name="dei:AmendmentFlag" id="Fact_2101f6fe8e0a4ca1b162445f11f2124e" contextRef="c20220509to20220509" format="ixt:booleanfalse">false</ix:nonNumeric><ix:nonNumeric name="dei:EntityCentralIndexKey" id="Fact_a7f13b2fb43547c68edda33d2cea637d" contextRef="c20220509to20220509">0000748592</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="btx-20220509.xsd" xlink:type="simple"></link:schemaRef></ix:references><ix:resources><xbrli:context id="c20220509to20220509"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-09</xbrli:startDate><xbrli:endDate>2022-05-09</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>

  <div><span style="font-family: 'Times New Roman'; font-size: 10pt;"> </span></div>

  <hr style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;" />
  <div>
    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 14pt; font-weight: bold;">UNITED STATES<br />
    </div>

    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 14pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>

    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 12pt; font-weight: bold;">Washington, D.C. 20549</div>

    <div style="text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman';"> <br />
      </span></div>

    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 18pt; font-weight: bold;">FORM <ix:nonNumeric name="dei:DocumentType" id="Fact_9541381f3e5044e1928bdf3aadd25573" contextRef="c20220509to20220509">8-K</ix:nonNumeric></div>

    <div style="text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman';"> <br />
      </span></div>

    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">CURRENT REPORT</div>

    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</div>

    <div style="text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman';"> <br />
      </span></div>

    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">Date of Report (Date of earliest event reported): <span style="font-weight: bold;"><ix:nonNumeric name="dei:DocumentPeriodEndDate" id="Fact_8f44890b52db416ea26adbf19a53f3d0" contextRef="c20220509to20220509" format="ixt:datemonthdayyearen">May 9, 2022</ix:nonNumeric></span></div>

    <div style="text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman';"> <br />
      </span></div>

    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 24pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityRegistrantName" id="Fact_3ba92018f4e74a0f9ca50c9fddf4d99c" contextRef="c20220509to20220509">Brooklyn ImmunoTherapeutics, Inc.</ix:nonNumeric><br />
    </div>

    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">(Exact Name of Registrant as Specified in its Charter)</div>

    <div style="text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman';"> <br />
      </span></div>

    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 32.61%; vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;">
            <div style="text-align: center; font-weight: bold;"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" id="Fact_8149dc346d2742cd95ef25b933806503" contextRef="c20220509to20220509" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric><br />
            </div>
          </td>

    <td style="width: 33.68%; vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;">
            <div style="text-align: center; font-weight: bold;"><ix:nonNumeric name="dei:EntityFileNumber" id="Fact_eef9553a254a495dbd09e81da27720ab" contextRef="c20220509to20220509">001-11460</ix:nonNumeric><br />
            </div>
          </td>

    <td style="width: 33.72%; vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;">
            <div style="text-align: center; font-weight: bold;"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" id="Fact_82e70fdfd38f4529bb322e982aecf2a6" contextRef="c20220509to20220509">31-1103425</ix:nonNumeric><br />
            </div>
          </td>

  </tr>

  <tr>

    <td style="width: 32.61%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
            <div style="text-align: center; font-style: italic;">(State or Other Jurisdiction of Incorporation)</div>
          </td>

    <td style="width: 33.68%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
            <div style="text-align: center; font-style: italic;">(Commission File Number)</div>
          </td>

    <td style="width: 33.72%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
            <div style="text-align: center; font-style: italic;">(IRS Employer Identification No.)</div>
          </td>

  </tr>


</table>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
    </div>

    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 49.01%; vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;">
            <div style="text-align: center; font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressAddressLine1" id="Fact_65b0595fd12c4b3a82cc7838938cf3df" contextRef="c20220509to20220509">10355 Science Center Drive</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressAddressLine2" id="Fact_b764089a33cd430082fc7dfe89965374" contextRef="c20220509to20220509">Suite 150</ix:nonNumeric></div>
          </td>

    <td style="width: 2%; vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td style="width: 49%; vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 49.01%; vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;">
            <div style="text-align: center; font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressCityOrTown" id="Fact_7c2ca66e7ec9429d9ecac53bcc2fb202" contextRef="c20220509to20220509">San Diego</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" id="Fact_5d7a34548b4a4f82b5eb8f46ec617f50" contextRef="c20220509to20220509" format="ixt-sec:stateprovnameen">California</ix:nonNumeric></div>
          </td>

    <td style="width: 2%; vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td style="width: 49%; vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;">
            <div style="text-align: center; font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" id="Fact_b580a48429994e65b24f1407abc886a8" contextRef="c20220509to20220509">92121</ix:nonNumeric><br />
            </div>
          </td>

  </tr>

  <tr>

    <td style="width: 49.01%; vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;">
            <div style="text-align: center; font-style: italic;">(Address of Principal Executive Offices)</div>
          </td>

    <td style="width: 2%; vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td style="width: 49%; vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;">
            <div style="text-align: center; font-style: italic;">(Zip Code)</div>
          </td>

  </tr>


</table>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
    </div>

    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">Registrant&#8217;s telephone number, including area code: <span style="font-weight: bold;">(<ix:nonNumeric name="dei:CityAreaCode" id="Fact_f39f70719f0243c98c0e5feced9b86d2" contextRef="c20220509to20220509">212</ix:nonNumeric>) <ix:nonNumeric name="dei:LocalPhoneNumber" id="Fact_5d73a04312fc4188bf7099f779c79423" contextRef="c20220509to20220509">582-1199</ix:nonNumeric></span></div>

    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
    </div>

    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following
      provisions:</div>

    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
    </div>

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="dei:WrittenCommunications" id="Fact_d5389ed488ca40e383869de29fb59653" contextRef="c20220509to20220509" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric></td>

    <td style="width: auto; vertical-align: top; text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">
            <div>Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</div>
          </td>

  </tr>


</table>
    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="dei:SolicitingMaterial" id="Fact_30f9d8a7d5504141976b73fea8d43d70" contextRef="c20220509to20220509" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric></td>

    <td style="width: auto; vertical-align: top; text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">
            <div>Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</div>
          </td>

  </tr>


</table>
    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="dei:PreCommencementTenderOffer" id="Fact_e4aa2395c73e49d283165c88d4e43bd8" contextRef="c20220509to20220509" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric></td>

    <td style="width: auto; vertical-align: top; text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">
            <div>Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</div>
          </td>

  </tr>


</table>
    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" id="Fact_12531d3145254f398dce72f468bc9ae7" contextRef="c20220509to20220509" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric></td>

    <td style="width: auto; vertical-align: top; text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">
            <div>Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</div>
          </td>

  </tr>


</table>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
    </div>

    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Securities registered pursuant to Section 12(b) of the Act:</div>

    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
    </div>

    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 41.3%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">
            <div style="text-align: center; font-weight: bold;">Title of each class</div>
          </td>

    <td style="width: 2%; vertical-align: middle; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td style="width: 18%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">
            <div style="text-align: center; font-weight: bold;">Trading symbol</div>
          </td>

    <td style="width: 2%; vertical-align: middle; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td style="width: 36.98%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">
            <div style="text-align: center; font-weight: bold;">Name of each exchange on which registered</div>
          </td>

  </tr>

  <tr>

    <td style="width: 41.3%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
            <div style="text-align: center;"><ix:nonNumeric name="dei:Security12bTitle" id="Fact_8a1c9d7128624a659679ba07ed3de93e" contextRef="c20220509to20220509">Common Stock, par value $0.005 per share</ix:nonNumeric><br />
            </div>
          </td>

    <td style="width: 2%; vertical-align: middle; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td style="width: 18%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
            <div style="text-align: center;"><ix:nonNumeric name="dei:TradingSymbol" id="Fact_3efaf9344c934859a35fab3e73b74f42" contextRef="c20220509to20220509">BTX</ix:nonNumeric><br />
            </div>
          </td>

    <td style="width: 2%; vertical-align: middle; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td style="width: 36.98%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
            <div style="text-align: center;"><ix:nonNumeric name="dei:SecurityExchangeName" id="Fact_a04be28562dc4082904d7bb16eceac7d" contextRef="c20220509to20220509" format="ixt-sec:exchnameen">The Nasdaq Stock Market LLC</ix:nonNumeric><br />
            </div>
          </td>

  </tr>


</table>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
    </div>

    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange
      Act of 1934:</div>

    <div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt;">Emerging growth company <ix:nonNumeric name="dei:EntityEmergingGrowthCompany" id="Fact_e8e07683774d4292ad647bd5ebbf3c9b" contextRef="c20220509to20220509" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric></div>

    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
    </div>

    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised
      financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</div>

    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"> <br />
    </div>

    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">
      <hr style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;" /> </div>

    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
      <div style="page-break-after:always;" class="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

    </div>

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 72pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Item 5.02</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"><span style="font-size: 10pt; font-family: 'Times New Roman';">Departure of Directors or Certain Officers; Election of Directors;
                Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</span></div>
          </td>

  </tr>


</table>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

    <div>
      <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="text-decoration: underline;">Appointment of Interim President and Chief Executive Officer</span></div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

    </div>

    <div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">On May </span><span style="font-family: 'Times New Roman'; font-size: 10pt;">24<span style="color: rgb(0, 0, 0);">, 2022, the Board of Directors (the &#8220;<span style="text-decoration: underline;">Board</span>&#8221;) of </span>Brooklyn ImmunoTherapeutics, Inc., a Delaware corporation (the &#8220;<span style="text-decoration: underline;">Company</span>&#8221;),<span style="color: rgb(0, 0, 0);">
            appointed Matthew Angel as the interim President and Chief Executive Officer (principal executive officer) of the Company, which appointment became effective on May </span>26<span style="color: rgb(0, 0, 0);">, 2022, upon the effectiveness of
            the resignation from the Company of Howard J. Federoff, M.D., Ph.D., as described below.</span></span></div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <div style="text-align: justify; text-indent: 36pt; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman';">Dr. Angel, 41 years old, is the co-founder of Factor
          Bioscience Inc. (&#8220;<span style="text-decoration: underline;">Factor</span>&#8221;), a biotechnology company focused on developing mRNA and cell-engineering technologies, and has served as its President, Chief Executive Officer and Chairman of its Board of Directors since 2011. In 2020, Dr.
          Angel co-founded, Exacis Biotherapeutics Inc., an immuno-oncology company, for which he serves as the Scientific Advisory Board Chair. Dr. Angel previously served as the Chief Science Officer, Secretary, Treasurer and as a director of Exacis
          Biotherapeutics Inc., and as the Chief Science Officer, Secretary and as a director of Novellus, Inc. (&#8220;<span style="text-decoration: underline;">Novellus</span>&#8221;), a pre-clinical stage biotechnology company focused on developing engineered cellular medicines using its licensed, patented
          non-immunogenic mRNA, from 2014 until the sale of Novellus to the Company in July 2021 (the &#8220;<span style="text-decoration: underline;">Novellus Acquisition</span>&#8221;). Dr. Angel received a Ph.D from the Massachusetts Institute of Technology in 2012 and a B.S. in Engineering from Princeton
          University in 2003.</span></div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <div style="text-align: justify; text-indent: 36pt; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman';">As previously reported, the Company paid consideration
          totaling approximately $124.0 million in respect of the Novellus Acquisition, which consisted of (a) $22.8 million in cash and (b) approximately 7,022,000 shares of the Company&#8217;s common stock, par value $0.005 per share (&#8220;<span style="text-decoration: underline;">common stock</span>&#8221;),
          which under the terms of the agreement and plan of acquisition, dated as of July 16, 2021, by and between the Company, Novellus and the other parties thereto (the &#8220;<span style="text-decoration: underline;">Novellus Acquisition Agreement</span>&#8221;), were valued at a total of $102.0 million,
          based on a price of $14.5253 per share of common stock. In connection with the Novellus Acquisition, (i) Factor, of which Dr. Angel beneficially owns approximately 64% of its outstanding equity, received approximately $1.7 million in cash
          consideration from the Company and approximately 2,581,000 shares of common stock, and (ii) Dr. Angel received approximately $2.0 million in cash consideration from the Company and approximately 623,000 shares of common stock. In addition, Dr.
          Angel is also entitled to receive up to approximately 286,000 shares of common stock, which the Company placed in escrow for a period ending on July 16, 2022 to secure indemnification obligations to the Company under the Novellus Acquisition
          Agreement.</span></div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <div style="text-align: justify; text-indent: 36pt; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman';">Also as previously reported, on April 26, 2021,
          Brooklyn ImmunoTherapeutics LLC (&#8220;<span style="text-decoration: underline;">Brooklyn LLC</span>&#8221;), a subsidiary of the Company, entered into an exclusive license agreement (the &#8220;<span style="text-decoration: underline;">License Agreement</span>&#8221;), with Novellus, Ltd., a subsidiary of Novellus, and Factor (the &#8220;<span style="text-decoration: underline;">Licensors</span>&#8221;),







          to license the Licensors&#8217; intellectual property and mRNA cell reprogramming and gene editing technology for use in the development of certain cell-based therapies to be evaluated and developed for treating human diseases, including certain types
          of cancer, sickle cell disease, and beta thalassemia. Pursuant to the License Agreement, Brooklyn LLC paid the Licensors a total of $4.0 million in connection with the execution of the License Agreement. The completion of the Novellus Acquisition
          relieved the Company of potential obligations to pay Novellus, Ltd. certain upfront fees, clinical development milestone fees and post-registration royalties under the License Agreement. The agreements with Factor under the License Agreement
          remain unchanged. Pursuant to the License Agreement, Brooklyn LLC paid Factor an additional $2.5 million in October 2021, and is obligated to pay Factor $3.5 million in October 2022.</span></div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">There are no family relationships between Dr. Angel and any director or executive officer of the Company, and, except as set
        forth above, Dr. Angel does not have any other direct or indirect material interest in any transaction or proposed transaction required to be reported under Item 404(a) of Regulation S-K. There are no arrangements or understandings between Dr.
        Angel and any other persons pursuant to which he was selected as interim Chief Executive Officer and President.</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

    </div>

    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
      <div style="page-break-after:always;" class="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

    </div>

    <div>
      <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="text-decoration: underline;">Appointment of New Chief Financial Officer and Principal Financial Officer</span></div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

    </div>

    <div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">On May </span><span style="font-family: 'Times New Roman'; font-size: 10pt;">9<span style="color: rgb(0, 0, 0);">, 2022, the Board appointed Andrew Jackson as the Chief Financial Officer (principal financial officer) of the Company, with such appointment becoming effective upon Mr. Jackson&#8217;s
            employment with the Company, which commenced May </span>31<span style="color: rgb(0, 0, 0);">, 2022.&#160; Sandra Gurrola, the Company&#8217;s Vice President, Finance, who had been serving as principal financial officer, will remain the Company&#8217;s
            principal accounting officer.&#160; In reliance on the </span>instructions<span style="color: rgb(0, 0, 0);"> to paragraph (c) of Item 5.02 of Form 8-K, the Company elected to </span>delay <span style="color: rgb(0, 0, 0);">the filing of the
            disclosure regarding Mr. Jackson&#8217;s appointment until the issuance of the press release describing his appointment, discussed in Item 7.01 below.</span></span></div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <div style="text-align: justify; text-indent: 36pt; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman';">Mr. Jackson, 53 years old, served as the Chief
          Financial Officer of Ra Medical Systems, Inc. from April 2018 until May 2022, and as its Secretary from August 2021 to May 2022. From October 2016 to April 2018, he was Chief Financial Officer for AltheaDx, Inc, a molecular diagnostics company
          specializing in precision medicine. From March 2014 to March 2016, Mr. Jackson held senior financial positions, including Chief Financial Officer, at Celladon Corporation, a publicly-traded, clinical stage biotechnology company. From April 2013
          to March 2014, he held senior financial positions at Sapphire Energy, an industrial biotechnology company. Mr. Jackson received a MSBA in Finance in December 2006 from San Diego State University and a BSB in Accounting in June 1992 from the
          University of Minnesota. Mr. Jackson is also a certified public accountant (inactive).</span></div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

    </div>

    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">In connection with his appointment as Chief
        Financial Officer, the Company entered into an employment agreement with Mr. Jackson, dated as of May 10, 2022 (the &#8220;<span style="text-decoration: underline;">Jackson Employment Agreement</span>&#8221;). The Jackson Employment Agreement provides for Mr. Jackson&#8217;s at-will employment as the Chief
        Financial Officer for a term commencing on May </span><span style="font-family: 'Times New Roman'; font-size: 10pt;">31<span style="color: rgb(0, 0, 0);">, 2022 and continuing until terminated by either the Company or Mr. Jackson. Under the terms
          of the Jackson Employment Agreement, the Company will pay Mr. Jackson an annual base salary of $415,000, which amount is subject to periodic review by the Board or its compensation committee (the &#8220;<span style="text-decoration: underline;">Compensation Committee</span>&#8221;). Mr. Jackson is
          eligible to receive an annual cash bonus award in an amount up to 40% of his base salary upon achievement of agreed upon performance targets. The bonus will be determined by the Board or the Compensation Committee and paid annually by March 15 in
          the year following the performance year on which such bonus is based.</span></span></div>

    <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

    <div>
      <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">In accordance with the terms of the Jackson Employment Agreement, Mr. Jackson is entitled to receive equity awards, consisting
        of a time-based nonqualified stock option (the &#8220;<span style="text-decoration: underline;">Option Grant</span>&#8221;) covering 664,800 shares of common stock, 25% of which will vest on the first anniversary of the Jackson Employment Agreement&#8217;s effective date, and the remainder will vest ratably
        on a monthly basis over the three-year period thereafter. Vesting generally requires Mr. Jackson&#8217;s continued employment through the relevant vesting date.</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">If Mr. Jackson&#8217;s employment is terminated by the Company without Cause or by Mr. Jackson for Good Reason (each such capitalized
        term as defined in the Jackson Employment Agreement), then the Company will pay Mr. Jackson all amounts accrued but unpaid as of the effective date of such termination, as well as continuation of his salary and benefits for the following nine month
        period (such period, the &#8220;<span style="text-decoration: underline;">Severance Period</span>&#8221;). Notwithstanding the foregoing, if a termination without Cause or for Good Reason occurs within three months before or twelve months after a Change in Control (as defined in the Jackson Employment
        Agreement), Mr. Jackson will receive the benefits described in the preceding sentence, but the Severance Period shall run for a period of twelve months, and, in addition, Mr. Jackson will receive a lump-sum payment of his target bonus and the
        Option Grant shall become fully vested. Any such severance benefits under the executive employment agreement are contingent on Mr. Jackson entering into and not revoking a general release of claims in favor of the Company.</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The Jackson Employment Agreement provides for (a) reimbursement of reasonable business expenses, (b) participation in the
        Company&#8217;s benefit plans and (c) paid vacation days in accordance with the Company&#8217;s policies, as in effect from time to time, and up to an additional seven floating paid vacation days a year.</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The Jackson Employment Agreement contains customary covenants related to non-solicitation for one year following termination of
        employment, as well as customary covenants related to non-competition, confidentiality, inventions and intellectual property rights.</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">There are no family relationships between Mr. Jackson and any director or executive officer of the Company, and, except for the
        Jackson Employment Agreement, Mr. Jackson does not have any other direct or indirect material interest in any transaction or proposed transaction required to be reported under Item 404(a) of Regulation S-K. There are no arrangements or
        understandings between Mr. Jackson and any other persons pursuant to which he was selected as the Chief Financial Officer.</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

    </div>

    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
      <div style="page-break-after:always;" class="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

    </div>

    <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="text-decoration: underline;">Separation of Dr. Howard Federoff</span></div>

    <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

    <div>
      <div style="text-align: justify; text-indent: 24.5pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">On May 24, 2022, Dr. Howard J. Federoff, a
          director and the Company&#8217;s Chief Executive Officer and President tendered his resignation to the Board, with such resignation becoming effective on May 26, 2022 (the &#8220;<span style="text-decoration: underline;">Separation Date</span>&#8221;).&#160; In connection with Dr. Federoff&#8217;s resignation, on
          May </span><span style="font-family: 'Times New Roman'; font-size: 10pt;">25<span style="color: rgb(0, 0, 0);">, 2022, the Company entered into a Separation Agreement and General Release with Dr. Federoff (the &#8220;<span style="text-decoration: underline;">Separation Agreement</span>&#8221;),
            pursuant to which Dr. Federoff resigned from his positions as Chief Executive Officer and as an officer, director and employee of the Company and all subsidiaries.&#160; Dr. Federoff&#8217;s resignation from the Board was not due to any disagreement with
            the Company on any matter relating to the Company&#8217;s operations, policies or practices. In consideration for Dr. Federoff&#8217;s execution of the Separation Agreement and non-revocation of a waiver and release of claims relating thereto, Dr. Federoff
            will be entitled to the following benefits under the Separation Agreement:</span></span></div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
      </div>

    </div>

    <div>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 42.5pt; font-family: 'Times New Roman'; font-size: 10pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">a lump sum cash severance benefit in the amount of $</span><span style="font-family: 'Times New Roman'; font-size: 10pt;">225,000<span style="color: rgb(0, 0, 0);">, representing Dr. Federoff&#8217;s target bonus for 2022;</span></span></div>
            </td>

  </tr>


</table>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 42.5pt; font-family: 'Times New Roman'; font-size: 10pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">
              <div>payment of Dr. Federoff&#8217;s annual base salary for a period of twelve (12) months after the expiration of the applicable revocation period (the &#8220;<span style="text-decoration: underline;">Separation Period</span>&#8221;), for a total gross amount equal to $450,000;</div>
            </td>

  </tr>


</table>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 42.5pt; font-family: 'Times New Roman'; font-size: 10pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="color: rgb(0, 0, 0);">payment of Dr. Federoff&#8217;s premiums for continued health benefits provided under COBRA for the Separation Period;</div>
            </td>

  </tr>


</table>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 42.5pt; font-family: 'Times New Roman'; font-size: 10pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">full acceleration of the vesting of all outstanding options (with the exception of
                  the Milestone Options, as defined below) that would have vested during the Separation Period, and such options, together with outstanding options that vested prior to the Separation Date, representing collectively 1,420,095 shares of
                  common stock,</span><span style="font-family: 'Times New Roman'; font-size: 10pt;"> may be exercised for a period of thirty-six (36) months after the Separation Date<span style="color: rgb(0, 0, 0);">;</span></span></div>
            </td>

  </tr>


</table>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 42.5pt; font-family: 'Times New Roman'; font-size: 10pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">acceleration and vesting of </span><span style="font-family: 'Times New Roman'; font-size: 10pt;">25/36<sup>th</sup><span style="color: rgb(0, 0, 0);"> of a performance-based stock option grant covering 597,253 shares of common stock, eligible to vest upon the occurrence of the first approval (clearance) by the Food
                    and Drug Administration of an investigational new drug application in connection with the Company&#8217;s license with Factor Biosciences Therapeutics Limited and Novellus Therapeutics Limited (the &#8220;<span style="text-decoration: underline;">Milestone Options</span>&#8221;), and such
                    accelerated options, representing collectively </span>414,759 shares of common stock, may be exercised for a period of thirty-six (36) months after the Separation Date; <span style="color: rgb(0, 0, 0);">and</span></span></div>
            </td>

  </tr>


</table>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 42.5pt; font-family: 'Times New Roman'; font-size: 10pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">a lump sum cash severance benefit in the amount of $</span><span style="font-family: 'Times New Roman'; font-size: 10pt;">130,347<span style="color: rgb(0, 0, 0);">, representing the </span>value Dr. Federoff would have received if he was entitled to receive a settlement of a pro rata portion of his
                  performance restricted stock units through the expiration of the Separation Period, assuming the performance metrics were waived and assuming a per share value of $0.81<span style="color: rgb(0, 0, 0);">.</span></span></div>
            </td>

  </tr>


</table>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

    </div>

    <div>
      <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Under the Separation Agreement, Dr. Federoff has agreed to cooperate with and assist the Company regarding certain matters and
        transitioning his employment duties and responsibilities. Subject to certain exceptions and limitations, the Separation Agreement includes a general release of claims by Dr. Federoff in favor of the Company and certain related persons and parties,
        and customary confidentiality and mutual non-disparagement provisions. The Separation Agreement also includes certain other customary representations, warranties and covenants of Dr. Federoff, and provides for reimbursement of certain expenses
        incurred by Dr Federoff. The Separation Agreement supersedes all other agreements or arrangements between Dr. Federoff and the Company regarding the subject matter of the agreement, including those with respect to severance payments and benefits.</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <div style="text-align: justify; text-indent: 36pt; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman';">The foregoing description of the Jackson Employment
          Agreement&#160;and the Separation Agreement is only a summary and is qualified in its entirety by reference to the full text of such agreements, which are filed as Exhibits 10.1 and 10.2, respectively, to this Current Report on Form 8-K and are
          incorporated by reference in this Item 5.02.</span></div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

    </div>

    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
      <div style="page-break-after:always;" class="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

    </div>

    <div>
      <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="text-decoration: underline;">Departures of Certain Directors</span></div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

    </div>

    <div>
      <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">On May 24, 2022, Heather Redman, Erich Mohr and Erin Enright delivered notices to the Board of their respective decisions not
        to stand for reelection at the Company&#8217;s 2022 annual meeting of stockholders (the &#8220;<span style="text-decoration: underline;">Annual Meeting</span>&#8221;), currently scheduled for June 7, 2022.&#160; On May 26, 2022, Dennis Langer similarly delivered notice to the Board of his decision not to stand
        for reelection at the Annual Meeting.&#160; As described in Item 8.01 of this Current Report on Form 8-K, the Annual Meeting will be postponed to a date to be determined by the Board.</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Ms. Redman, Ms. Enright, Dr. Mohr and Dr. Langer currently remain directors, and none of them has yet provided a specific date
        on which his or her Board service will cease, as the current Board actively interviews and seeks new candidates with appropriate qualifications to serve on the Board.&#160; The decisions of the foregoing directors not to stand for reelection were not
        due to any disagreement with the Company on any matter relating to the Company&#8217;s operations, policies or practices.</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

    </div>

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 72pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Item 7.01</td>

    <td style="width: auto; vertical-align: top; text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">
            <div style="color: rgb(0, 0, 0); font-weight: bold;">Regulation FD Disclosure</div>
          </td>

  </tr>


</table>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

    <div>
      <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">On May 31, 2022, the Company issued a press release relating to the matters described in Item 5.02 and Item 8.01 of this
        Current Report on Form 8-K. A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and incorporated by reference in this Item 7.01. The information contained in this Item 7.01, including Exhibit 99.1, is
        furnished and shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;<span style="text-decoration: underline;">Exchange Act</span>&#8221;), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by
        reference into any registration statement or other filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing, except as shall be expressly incorporated by specific
        reference in such filing.</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

    </div>

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 72pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Item 8.01</td>

    <td style="width: auto; vertical-align: top; text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">
            <div style="color: rgb(0, 0, 0); font-weight: bold;">Other Events</div>
          </td>

  </tr>


</table>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

    <div>
      <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">In connection with the events disclosed in Item 5.02 of this Current Report on Form 8-K, the Board determined to postpone the
        Annual Meeting to a date to be determined. The Board will both determine the date for the Annual Meeting and establish a new record date for the Annual Meeting, and, based on this record date, the Company will deliver a new notice of the Annual
        Meeting to stockholders entitled to receive notice of the Annual Meeting.&#160; Additionally, the Company expects to file a new proxy statement on Schedule 14A in respect of the Annual Meeting.</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

    </div>

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 72pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Item 9.01</td>

    <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">
            <div style="font-weight: bold;">Financial Statements and Exhibits.</div>
          </td>

  </tr>


</table>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">(d) Exhibits.</div>

    <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 9.91%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div>
              <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Exhibit</div>
              <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Number</div>
            </div>
          </td>

    <td style="width: 2.37%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; padding-bottom: 2px;">&#160;</td>

    <td style="width: 87.71%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; text-align: center;">
            <div>
              <div style="font-weight: bold;">Description</div>
            </div>
          </td>

  </tr>

  <tr>

    <td style="width: 9.91%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
            <div style="text-align: center;"><a href="brhc10038309_ex10-1.htm">10.1**</a></div>
          </td>

    <td style="width: 2.37%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td style="width: 87.71%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
            <div style="text-align: justify;">Amended and Restated Executive Employment Agreement, dated as of May 10, 2022, by and between Brooklyn ImmunoTherapeutics, Inc. and Andrew Jackson.</div>
          </td>

  </tr>

  <tr>

    <td style="width: 9.91%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
            <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 10pt;"><a href="brhc10038309_ex10-2.htm">10.2** #</a></div>
            <div>&#160;</div>
          </td>

    <td style="width: 2.37%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td style="width: 87.71%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
            <div style="text-align: justify;">Separation Agreement and General Release, dated May 25, 2022, by and between Brooklyn ImmunoTherapeutics, Inc. and Howard J. Federoff.</div>
          </td>

  </tr>

  <tr>

    <td style="width: 9.91%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
            <div style="text-align: center;"><a href="brhc10038309_ex99-1.htm">99.1</a></div>
          </td>

    <td style="width: 2.37%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td style="width: 87.71%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
            <div style="text-align: justify;">Press Release dated May 31, 2022</div>
          </td>

  </tr>

  <tr>

    <td style="width: 9.91%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
            <div style="text-align: center;">104</div>
          </td>

    <td style="width: 2.37%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td style="width: 87.71%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
            <div style="text-align: justify;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</div>
          </td>

  </tr>


</table>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
    </div>

    <div>
      <table cellspacing="0" cellpadding="0" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" class="DSPFListTable">


  <tr style="vertical-align: top;">

    <td style="vertical-align: top; width: 18pt;">
              <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">**</div>
            </td>

    <td style="align: left; vertical-align: top; width: auto;">
              <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Management contract or compensation plan or arrangement.</div>
            </td>

  </tr>


</table>
    </div>

    <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

    <div style="font-family: 'Times New Roman'; font-size: 10pt;">
      <div style="text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">#</span>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Pursuant to Item 601(a)(5) of Regulation S-K, schedules and similar attachments to this exhibit have been omitted because they do not contain information material to an
            investment or voting decision and such information is not otherwise disclosed in such exhibit.</span><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;">&#160;</span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">The Company will supplementally provide a copy of any omitted schedule or similar attachment to the U.S. Securities and Exchange Commission or its staff upon request.</span></span></div>

    </div>

    <div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br />
    </div>

    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
      <div style="page-break-after:always;" class="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

    </div>

    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">SIGNATURE</div>

    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
    </div>

    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto
      duly authorized.</div>

    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
    </div>

    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 49.72%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td style="vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;" colspan="2">
            <div style="text-align: left; font-variant: small-caps;">Brooklyn ImmunoTherapeutics, Inc.</div>
          </td>

  </tr>

  <tr>

    <td style="width: 49.72%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td style="vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;" colspan="2">&#160;</td>

  </tr>

  <tr>

    <td style="width: 49.72%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
            <div style="text-align: left;">Dated: <span style="color: rgb(0, 0, 0);">May 31, 2022</span></div>
          </td>

    <td style="width: 3%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
            <div style="text-align: left;">By:</div>
          </td>

    <td style="width: 47%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;" rowspan="1">
            <div style="text-align: left;">/s/ Dr. Matt Angel</div>
          </td>

  </tr>

  <tr>

    <td style="width: 49.72%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td style="width: 3%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td style="width: 47%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;" rowspan="1">
            <div style="text-align: left;">Interim Chief Executive Officer and President</div>
          </td>

  </tr>


</table>
    <div> <br />
    </div>

    <div> <br />
    </div>

    <div>
      <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; border: none; margin-left: auto; margin-right: auto;" /> </div>

  </div>

  <div><span style="font-family: 'Times New Roman'; font-size: 10pt;"> </span></div>

</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>brhc10038309_ex10-1.htm
<DESCRIPTION>EXHIBIT 10.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, Inc
         Document created using EDGARfilings PROfile 8.2.0.0
         Copyright 1995 - 2022 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <font style="font-size: 10pt;"> </font><!--PROfilePageNumberReset%Num%1%%%-->
  <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"><font style="font-size: 10pt;"> </font>
  <div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; font-weight: bold;">Exhibit 10.1</div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt;"><br>
      </font> </div>
    <div style="text-align: center; margin-right: 5.75pt; font-family: 'Times New Roman'; font-size: 10pt;">AMENDED AND RESTATED</div>
    <div style="text-align: center; margin-right: 5.75pt; font-family: 'Times New Roman'; font-size: 10pt;">EXECUTIVE EMPLOYMENT AGREEMENT</div>
    <div style="text-align: center; margin-right: 5.75pt; font-family: 'Times New Roman'; font-size: 10pt;">BROOKLYN IMMUNOTHERAPEUTICS, INC.</div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt;"><br>
      </font> </div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 36pt;">This AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT (this &#8220;<font style="font-weight: bold; font-style: italic;">Agreement</font>&#8221;) dated as of
      May 10, 2022, is entered by and between Brooklyn ImmunoTherapeutics, Inc., a Delaware corporation (the &#8220;<font style="font-weight: bold; font-style: italic;">Company</font>&#8221;), and Andrew Jackson, an individual residing in Cardiff, California 92007 (&#8220;<font style="font-weight: bold; font-style: italic;">Executive</font>&#8221;) and, except with respect to the amendment and restatement hereof contained in the Recitals (which are incorporated by reference and made an operative part of this Agreement), will
      become effective as of the date on which Executive commences his employment with the Company (the &#8220;<font style="font-weight: bold; font-style: italic;">Effective Date</font>&#8221;). Each of the Company and Executive is a &#8220;<font style="font-weight: bold; font-style: italic;">Party</font>,&#8221; and collectively, they are the &#8220;<font style="font-weight: bold; font-style: italic;">Parties</font>.&#8221;</div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
    <div style="margin: 0px 0px 0px 41pt; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;">WHEREAS, the Company wishes to employ Executive as of the Effective Date; and</div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
    <div style="margin: 0px 0px 0px 41pt; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;">WHEREAS, Executive wishes to be employed by the Company as of the Effective Date;</div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
    <div style="margin: 0px 0px 0px 41.05pt; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;">WHEREAS, a copy of this Agreement, intended for discussion and not for execution, was in fact executed by Executive and the Company on May
      4, 2022 (the &#8220;<u>Original Agreement</u>&#8221;), and, in accordance with Section 13 of the Original Agreement, the Company and Executive hereby agree that the Original Agreement is hereby amended and restated in its entirety as set forth in this Agreement.</div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 41pt;">NOW THEREFORE, in consideration of the above recitals, which are incorporated herein, the mutual covenants and mutual benefits set forth herein, and
      other good and valuable consideration, the receipt and sufficiency of which is acknowledged, the Company and Executive agree as follows: </div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">1.</font><font style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Representations











          and Warranties. </font>Executive represents and warrants to the Company that Executive is not bound by any restrictive covenants or other obligations or commitments of any kind that would in any way prevent, restrict, hinder or interfere with
        Executive&#8217;s acceptance of employment under the terms and conditions set forth herein or the performance of all duties and services hereunder to the fullest extent of Executive&#8217;s ability and knowledge. Executive understands and acknowledges that
        Executive is not expected or permitted to use or disclose confidential information belonging to any prior employer in the course of performing Executive&#8217;s duties for the Company.</font></div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">2.</font><font style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160; &#160; &#160; <font style="font-weight: bold;">Term











          of Employment. </font>As of the Effective Date, the Company will employ Executive and Executive accepts employment by the Company on the terms and conditions herein that shall commence on the Effective Date and shall continue until terminated
        pursuant to Section 5 (the &#8220;<font style="font-weight: bold; font-style: italic;">Employment Period</font>&#8221;). Notwithstanding anything set forth in Section 5 and for the avoidance of doubt, Executive&#8217;s employment is on an at-will basis, meaning that
        Executive or the Company can terminate Executive&#8217;s employment at any time for any reason or no reason, with or without notice. The at-will nature of Executive&#8217;s employment cannot be changed except by written agreement signed by Executive and the
        Company.</font></div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">1</font></div>
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0px; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0); clear: both;"></div>
    </div>
    <div>
      <div style="font-weight: bold; margin-left: 45pt; font-size: 10pt;">3.&#160;&#160;&#160;&#160;&#160; Duties and Functions.</div>
    </div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt; font-size: 10pt;"><font style="font-family: 'Times New Roman';">(a)&#160;&#160;&#160;&#160;&#160;&#160; Executive shall be employed as the Chief Financial Officer (&#8220;<font style="font-weight: bold; font-style: italic;">CFO</font>&#8221;)
        and shall report to the Chief Executive Officer/President (the &#8220;<font style="font-weight: bold; font-style: italic;">Supervisor</font>&#8221;). Executive&#8217;s primary place of employment shall be located at 10355 Science Center Drive, Suite 150, San Diego,
        California 92121 (&#8220;<font style="font-weight: bold; font-style: italic;">Primary Place of Employment</font>&#8221;). Notwithstanding the foregoing, (i) Executive must obtain advance written approval from Executive&#8217;s Supervisor if Executive desires to move
        Executive&#8217;s Primary Place of Employment to a different state, (ii) the Company and Executive shall periodically reevaluate Executive&#8217;s Primary Place of Employment, and (iii) the Company and Executive shall reevaluate Executive&#8217;s Primary Place of
        Employment if circumstances change, including if the COVID-19 pandemic materially changes or ends. Notwithstanding the foregoing,</font></div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;">&#160;Executive agrees that, as a result of these periodic evaluations or changes in circumstance, the Company may request that Executive consent to work primarily or
      partially from the Company&#8217;s facilities, which consent may not be unreasonably withheld.</div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt; font-size: 10pt;"><font style="font-family: 'Times New Roman';">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Executive agrees to undertake the duties and responsibilities inherent in the positions of CFO, which may encompass
        different or additional duties as may, from time to time, be assigned by Executive&#8217;s Supervisor, or the Supervisor&#8217;s designee, and the duties and responsibilities undertaken by Executive may be altered or modified from time to time by Supervisor,
        or by the Supervisor&#8217;s designee. Executive&#8217;s duties shall include but not be limited to those duties set forth on <u>Addendum A</u>. Executive agrees to abide by the rules, regulations, instructions, personnel practices and policies of the Company
        and any change thereof which may be adopted at any time by the Company. Notwithstanding the foregoing, during the COVID-19 pandemic, business related travel will be subject to the Supervisor&#8217;s and Executive&#8217;s good faith determination that business
        related travel is necessary. All applicable COVID-19 travel restrictions, state, local and federal health and safety guidelines, and Company policies should be considered in connection with any travel activities.</font></div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt; font-size: 10pt;"><font style="font-family: 'Times New Roman';">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;During the Employment Period, Executive will devote Executive&#8217;s full time and efforts to the business of the Company and
        will not, without the consent of the Company, engage in consulting work or any trade or business for Executive&#8217;s own account or for or on behalf of any other person, firm or corporation that competes, conflicts or interferes with the performance of
        Executive&#8217;s duties hereunder in any way.</font></div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
    <div>
      <div style="font-weight: bold; margin-left: 45pt; font-size: 10pt;">4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Compensation.</div>
    </div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt; font-size: 10pt;"><font style="font-family: 'Times New Roman';">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Base Salary</u>: As compensation for Executive&#8217;s services hereunder, the Company agrees to pay Executive a base salary
        at an annual rate of Four-Hundred fifteen thousand dollars ($415,000), payable in accordance with the Company&#8217;s normal payroll schedule, but in no event less frequently than monthly. Executive&#8217;s base salary shall be reviewed periodically by the
        Board or the Compensation Committee thereof and subject to increase in the Board&#8217;s and/or the Compensation Committee&#8217;s sole discretion.</font></div>
    <div style="text-align: justify; text-indent: 72pt; margin-left: 5pt; font-size: 10pt;"><font style="font-family: 'Times New Roman';"> <br>
      </font></div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">2</font></div>
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0px; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0); clear: both;"></div>
    </div>
    <div style="text-align: justify; text-indent: 72pt; font-size: 10pt;"><font style="font-family: 'Times New Roman';">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Bonus</u>: Beginning with calendar year 2022, Executive shall be eligible to receive an annual cash bonus award in an
        amount up to a target of forty percent (40%) of Executive&#8217;s base salary upon achievement of agreed to reasonable performance targets. Such performance targets shall be based in part upon performance of the Company, and in part on Executive&#8217;s
        individual performance. The bonus shall be determined by the Board or the Compensation Committee thereof in its sole discretion and paid annually by March 15 of the year following the performance year on which such bonus is based. Except as
        contemplated by Section 5(c)(i) below, Executive&#8217;s receipt of the bonus, if any, is conditioned on Executive&#8217;s continued employment in good standing as of the date on which such bonus is paid, and any such bonus will not be considered earned until
        such payment date. Executive&#8217;s bonus opportunity shall be reviewed annually by the Board or the Compensation Committee thereof and subject to adjustment to reflect Executive&#8217;s performance in the Board&#8217;s and/or the Compensation Committee&#8217;s sole
        discretion. Executive&#8217;s bonus for 2022 shall be prorated for the number of days of employment in calendar year 2022 from the Effective Date.</font></div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
    <div>
      <div style="font-family: 'Times New Roman'; font-size: 10pt; margin-left: 81pt;">(c) &#160; &#160;&#160; <font style="font-family: 'Times New Roman';"><u>Equity Compensation</u>:</font></div>
    </div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 108pt; font-size: 10pt;"><font style="font-family: 'Times New Roman';">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; On the Effective Date, in accordance with the employment inducement grant rules set forth in NASDAQ Stock Market Rule
        5635(c)(4), Executive shall be granted an equity award covering the Company&#8217;s common stock (collectively, the &#8220;<font style="font-weight: bold; font-style: italic;">Grant</font>&#8221;).</font></div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 108pt; font-size: 10pt;"><font style="font-family: 'Times New Roman';">(ii)&#160;&#160;&#160;&#160;&#160;&#160; The Company shall grant Executive a time-based nonqualified stock option grant (the &#8220;<font style="font-weight: bold; font-style: italic;">Option Grant</font>&#8221;) covering 664,800 shares of the Company&#8217;s common stock. The per share exercise price of the Option Grant shall equal the closing price of a share of the Company&#8217;s common stock on the grant date. The
        Option Grant shall vest as to twenty-five percent of the shares covered thereby on the first anniversary of the Effective Date, and 1/36 of the remaining shares covered thereby on each monthly anniversary of the Effective Date thereafter, in each
        case subject to Executive&#8217;s continued employment with the Company through the relevant vesting date.</font></div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 108pt; font-size: 10pt;"><font style="font-family: 'Times New Roman';">(iii)&#160;&#160;&#160;&#160;&#160; All other terms and conditions of the Option Grant shall be the same as the Company&#8217;s standard forms of grant agreements.
        The Option Grant is intended to constitute an &#8220;employment inducement grant&#8221; in accordance with the employment inducement grant rules set forth in NASDAQ Stock Market Rule 5635(c)(4), and are offered as an inducement material to Executive in
        connection with the Company&#8217;s hiring of Executive.</font></div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 108pt; font-size: 10pt;"><font style="font-family: 'Times New Roman';">(iv)&#160;&#160;&#160;&#160;&#160;&#160; Executive shall be eligible to receive an equity award under the applicable equity incentive plan of the Company as then in
        effect, as determined by the Compensation Committee based on Executive&#8217;s performance.</font></div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(d)&#160;&#160;&#160;&#160;&#160;&#160; <u>Other Expenses</u>: In addition to the compensation provided for above, the Company agrees to pay or to reimburse
        Executive during Executive&#8217;s employment for all reasonable, ordinary and necessary, properly documented, business expenses incurred in the performance of Executive&#8217;s services hereunder in accordance with Company policy in effect from time to time;
        provided, however, that the amount available to Executive for such travel, entertainment and other expenses may require advance approval from his Supervisor. Executive shall submit vouchers and receipts for all expenses for which reimbursement is
        sought. Notwithstanding any expense reimbursement policy of the Company that may then be in effect, Executive shall be entitled to reimbursement without advance approval by Executive&#8217;s Supervisor of the costs of (i) up to 2 professional conferences
        up to a total amount of $5,000 annually and (ii) all flights, which, when possible, shall be business class or better for all flights for Company travel over four hours in length. Executive shall also receive $50/month for costs associated with
        using Executive&#8217;s mobile device and home internet for business purposes pursuant to the Company&#8217;s Mobile Phone and Home Internet Policy.</font> </div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">3</font></div>
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0px; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0); clear: both;"></div>
    </div>
    <div style="text-align: justify; text-indent: 72pt; font-size: 10pt;"><font style="font-family: 'Times New Roman';">(e)&#160;&#160;&#160;&#160;&#160;&#160; &#160; <u>Paid Time Off and Paid Holidays</u>: Executive shall be entitled to paid time off in accordance with the Company&#8217;s
        policies, as in effect from time to time. Executive is eligible for flexible paid time off under the Company&#8217;s current policies.</font></div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 36pt;">In addition to the enumerated paid Company holidays, Executive shall also be entitled to up to seven (7) paid floating holidays per calendar year.
      Unused floating holidays can carry over from calendar year to calendar year up to a maximum of ten (10) floating holidays and shall be paid out upon separation of employment as required under applicable law. Once the 10-day floating holiday cap is
      reached, the Employee shall not be given any paid floating holidays until some are used.</div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 36pt;">Executive may also be entitled to additional paid or unpaid leave under Company policy and applicable law.</div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt; font-size: 10pt;"><font style="font-family: 'Times New Roman';">(f)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Fringe Benefits</u>. In addition to Executive&#8217;s compensation provided by the foregoing, Executive shall be entitled to
        all benefits available generally to Company employees pursuant to Company programs which may now or, if not terminated, shall hereafter be in effect, or that may be established by the Company, as and to the extent any such programs are or may from
        time to time be in effect, as determined by the Company and the terms hereof, subject to the applicable terms and conditions of the benefit plans in effect at that time. Nothing herein shall affect the Company&#8217;s ability to modify, alter, terminate
        or otherwise change any benefit plan it has in effect at any given time, to the extent permitted by law.</font></div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(g)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Reimbursements</u>. With respect to any reimbursement of expenses of Executive, such reimbursement of expenses shall be
        subject to the following conditions: (i) the expenses eligible for reimbursement in one taxable year shall not affect the expenses eligible for reimbursement in any other taxable year; (ii) the reimbursement of an eligible expense shall be made no
        later than the end of the year after the year in which such expense was incurred; and</font><font style="font-size: 10pt;"> (iii) the right to reimbursement shall not be subject to liquidation or exchange for another benefit.</font></div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
    <div>
      <div style="font-weight: bold; margin-left: 45pt; font-size: 10pt;">5.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Termination.</div>
      <div style="font-weight: bold; margin-left: 45pt;"> <font style="font-size: 10pt;"><br>
        </font> </div>
    </div>
    <div style="text-align: justify; text-indent: 72pt; font-size: 10pt;"><font style="font-family: 'Times New Roman';">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Termination by Executive</u>. Executive may terminate the employment relationship at any time by giving the Company
        written notice, with such termination taking effect upon written notice of the termination being provided to the Company. If Executive chooses to terminate the employment relationship other than for Good Reason (defined below), Executive will not
        be entitled to and shall not receive any compensation or benefits of any type following the effective date of termination, other than (i) payment of base salary through the last day of employment, (ii) payment for any accrued but unused PTO and
        floating holidays consistent with this agreement and applicable law, (iii) reimbursement for unreimbursed business expenses properly incurred by Executive, which shall be subject to and paid in accordance with the Company&#8217;s expense reimbursement
        policy, and (iv) any right to continued benefits required by law or under the Company&#8217;s employee benefit plans and vested as of the termination date (the &#8220;<font style="font-weight: bold; font-style: italic;">Accrued Obligations</font>&#8221;). If
        Executive terminates the employment relationship for Good Reason (defined below), Executive will be entitled to the Accrued Obligations and the Non-CIC Termination Compensation or CIC Termination Compensation, as applicable and described below,
        subject to the terms, conditions and restrictions set forth in Section 5(c)(ii).</font></div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">4</font></div>
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0px; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0); clear: both;"></div>
    </div>
    <div style="text-align: justify; text-indent: 108pt; font-size: 10pt;"><font style="font-family: 'Times New Roman';">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<font style="font-weight: bold; font-style: italic;">Good Reason</font>&#8221; means the occurrence of any of the following
        without Executive&#8217;s express written consent: (A) a material reduction in Executive&#8217;s base salary or target annual bonus (in other words, a reduction of more than ten percent (10%) of Executive&#8217;s base salary or target annual bonus in any one year),
        in each case set forth in Section 4; (B) a relocation of Executive to a facility or location that is more than fifty (50) miles from Executive&#8217;s Primary Place of Employment as of the Effective Date and represents a material increase in Executive&#8217;s
        commuting distance; (C) a material diminution in Executive&#8217;s authority, position, duties, or responsibilities individually or taken as a whole and including any such diminution that takes place following a Change in Control; or (D) a material
        breach by the Company of the terms of this Agreement or any other agreement between the Company and Executive; provided, that no such event described above will constitute Good Reason unless: (x) Executive gives notice to the Company specifying the
        condition or event relied upon for such termination within sixty (60) days of the initial existence of such event; and (y) the Company fails to cure the condition or event constituting Good Reason within thirty (30) days following receipt of such
        notice (the &#8220;<font style="font-weight: bold; font-style: italic;">Cure Period</font>&#8221;). If the Company fails to remedy the condition constituting Good Reason during the applicable Cure Period, Executive&#8217;s termination of employment must occur, if at
        all, within ninety (90) days following the last day of such Cure Period in order for such termination as a result of such condition to constitute a termination for Good Reason. For purposes of this Agreement, &#8220;Change in Control&#8221; means as defined in
        the Company&#8217;s 2021 Inducement Stock Incentive Plan.</font></div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
    <div>
      <div style="font-family: 'Times New Roman'; font-size: 10pt; margin-left: 81pt;">(b)<font style="font-family: 'Times New Roman';">&#160;&#160;&#160;&#160;&#160;&#160; <u>Termination by Company for Cause</u>.</font></div>
    </div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
    <div style="font-size: 10pt; text-align: justify; text-indent: 108pt;"><font style="font-family: 'Times New Roman';">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160; At any time during the Employment Period, the Company may terminate Executive&#8217;s employment for Cause (defined below), with
        such termination taking effect upon the later of written notice of the termination for Cause being provided to Executive or the expiration of any applicable cure period related thereto (provided that Executive may be relieved from his duties
        hereunder during such cure period in the reasonable direction of the Board). If Executive&#8217;s employment is terminated for Cause, Executive will not be entitled to and shall not receive any compensation or benefits of any type following the effective
        date of termination, other than the Accrued Obligations, and shall forfeit the Option Grant, whether vested or unvested.</font></div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
    <div style="font-size: 10pt; text-align: justify; text-indent: 108pt;"><font style="font-family: 'Times New Roman';">(ii)&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold; font-style: italic;">Cause</font>&#8221; shall be defined as: (A) in connection with Executive&#8217;s
        services hereunder, Executive commits a material act of fraud or material act of dishonesty with respect to the Company, which act causes (or could reasonably be expected to cause) material economic or material reputational harm to the Company; (B)
        Executive is convicted of (or pleads guilty or nolo contendere to) a felony or a crime involving moral turpitude, which demonstrably causes material economic or material reputational harm to the Company; (C) Executive engages in negligence or
        willful misconduct in the performance of his duties hereunder that materially violates the Company&#8217;s policies and which misconduct causes (or could reasonably be expected to cause) material economic or material reputational harm to the Company; (D)
        Executive willfully refuses to follow the lawful written directions of his Supervisor, the Supervisor&#8217;s designee, or the Board; (E) Executive materially breaches any material provision of any proprietary information and inventions agreement with
        the Company; or (F) Executive breaches any Restrictive Covenant as defined in Section 5(c)(ii). Notwithstanding Section 5(b)(ii)(D), if Executive refuses to follow the Company&#8217;s request that Executive work primarily or partially from the Company&#8217;s
        facilities or another location, such refusal will only give the Company Cause to terminate the Executive <u>if</u> the facilities are located 50 miles or less from Executive&#8217;s Primary Place of Employment as of the Effective Date and represents a
        material increase in Executive&#8217;s commuting distance. Notwithstanding anything in this Agreement or elsewhere to the contrary, if an event or occurrence that is alleged to constitute Cause is curable (as determined by the Board in good faith), the
        Company may terminate Executive&#8217;s employment for Cause only if (x) the Company gives Executive notice of termination prior to the termination and within thirty (30) days after the Board learns of the event or occurrence that is alleged to
        constitute Cause, specifying the grounds upon which Cause is alleged, (y) Executive fails to cure such grounds for Cause within thirty (30) days after Executive receives such notice, and (z) the termination occurs within sixty (60) days after such
        event or occurrence. For purposes of this Agreement, no act or failure to act, on Executive&#8217;s part, will be considered &#8220;willful&#8221; unless it is done, or omitted to be done, by Executive in bad faith or without reasonable belief that Executive&#8217;s
        action or omission was in the best interests of the Company.</font></div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">5</font></div>
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0px; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0); clear: both;"></div>
    </div>
    <div>
      <div style="font-family: 'Times New Roman'; font-size: 10pt; margin-left: 81pt;">(c)<font style="font-family: 'Times New Roman';">&#160;&#160;&#160;&#160;&#160;&#160; <u>Termination by Company Without Cause</u>.</font></div>
    </div>
    <div> <font style="font-size: 10pt;"><br>
      </font> </div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 108pt;">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160; The Company may terminate Executive without Cause immediately by giving Executive written notice of such termination. Subject to the
      conditions set forth in Section 5(c)(ii), if Executive&#8217;s employment is terminated by the Company without Cause, in addition to the Accrued Obligations, Executive shall be entitled to (i) continued base salary for nine (9) months following date of
      such termination (the &#8220;<font style="font-weight: bold; font-style: italic;">Severance Period</font>&#8221;) paid pursuant to the Company's normal payroll practices; and (ii) if Executive and/or Executive&#8217;s covered dependents timely elect(s) to receive
      health care continuation coverage pursuant to COBRA, the total monthly cost of coverage for Executive (and such covered dependents) during the Severance Period, provided, for the avoidance of doubt, that such covered dependents participated in the
      Company&#8217;s health plans prior to such termination, and provided, further, that if at any time the Company determines that its payment of Executive&#8217;s (or Executive&#8217;s eligible dependents&#8217;) premiums would result in a violation of law, then in lieu of
      providing the premiums described above, the Company will instead pay Executive a fully taxable monthly cash payment in an amount equal to the applicable premiums for such month, with such monthly payment being made on the last day of each month for
      the remainder of the Severance Period (together, the &#8220;<font style="font-weight: bold; font-style: italic;">Non-CIC Termination Compensation</font>&#8221;). Notwithstanding the foregoing, if Executive&#8217;s employment is terminated by the Company without Cause
      or by Executive for Good Reason, in each case during the ninety (90) days prior to or twelve (12) month period following a Change in Control, (i) the Executive shall receive the Non-CIC Termination Compensation as described above except that the
      Severance Period shall equal twelve (12) months in lieu of nine (9) months, (ii) Executive shall receive a lump-sum payment of Executive&#8217;s target annual bonus and (iii) Executive shall become fully vested in the Option Grant (together, the &#8220;<font style="font-weight: bold; font-style: italic;">CIC Termination Compensation</font>&#8221;). The Non-CIC Termination Compensation and the CIC Termination Compensation shall, as applicable and in each case, be subject to the terms, conditions and
      restrictions set forth below in Section 5(c)(ii).</div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">6</font></div>
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0px; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0); clear: both;"></div>
    </div>
    <div style="font-size: 10pt; text-align: justify; text-indent: 108pt;"><font style="font-family: 'Times New Roman';">(ii)&#160;&#160;&#160; &#160;&#160; Executive shall not be entitled to any Non-CIC Termination Compensation or CIC Termination Compensation unless (A) Executive
        complies with all surviving provisions of any non-competition agreement, non-solicitation agreement, or confidentiality agreement or invention assignment agreement signed by Executive, including those contained in this Agreement (the &#8220;<font style="font-weight: bold; font-style: italic;">Restrictive Covenants</font>&#8221;) and (B) Executive executes and delivers to the Company, and does not revoke a separation agreement and general release in form and substance reasonably acceptable to
        the Company within thirty (30) days after Executive&#8217;s separation date, by which Executive releases the Company from any obligations and liabilities of any type whatsoever, except for the Company&#8217;s obligations with respect to, as applicable, the
        Non- CIC Termination Compensation or the CIC Termination Compensation (the &#8220;<font style="font-weight: bold; font-style: italic;">Release</font>&#8221;). Such Release shall not affect Executive&#8217;s right to indemnification, if any, for actions taken within
        the scope of Executive&#8217;s employment. The Non-CIC Termination Compensation or the CIC Termination Compensation, as applicable, shall begin, or if lump-sum, be paid on the first payroll following the Release becoming irrevocable; provided, however,
        if the thirty (30) day period during which Executive has discretion to execute or revoke the Release straddles two taxable years of Executive, then the Company shall pay the Non-CIC Termination Compensation or the CIC Termination Compensation, as
        applicable, starting in the second of such taxable years, regardless of which taxable year Executive actually delivers the executed Release to the Company. The Parties hereto acknowledge that the Non-CIC Termination Compensation and the CIC
        Termination Compensation, as applicable, to be provided under Section 5(c)(i) is to be provided in consideration for the above-specified Release. If Executive breaches any of the Restrictive Covenants at any time during the Severance Period, (1)
        the Company will have no further obligation to pay Executive any unpaid Non-CIC Termination Compensation or CIC Termination Compensation, as applicable, (2) Executive must repay any portion of the Non-CIC Termination Compensation or the CIC
        Termination Compensation, as applicable, already paid to him, to the extent permitted by law, and (3) the Company may take any additional action to enforce its rights under the Restrictive Covenants. Finally, if Executive becomes employed during
        the Severance Period, Executive will only be entitled to receive an amount equal to the difference between his new base salary and his continued base salary from the Company. He will not be entitled to his continued base salary from the Company if
        his new base salary is equal to or exceeds his continued base salary from the Company.</font></div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
    <div style="font-size: 10pt; text-align: justify; text-indent: 108pt;"><font style="font-family: 'Times New Roman';">(iii)&#160;&#160;&#160; <u>Disqualification for Other Severance</u>. The Non-CIC Termination Compensation and the CIC Termination Compensation
        described in this Section 5(c) is intended to supersede any other similar compensation provided by any Company policy, plan or practice. Therefore, Executive shall be disqualified from receiving any similar compensation under any other Company
        severance policy, plan or practice, if any. Notwithstanding the foregoing, Executive shall continue to be eligible for any benefits pursuant to the terms of any health or retirement plan sponsored by the Company, subject to and in accordance with
        the terms of the applicable plan.</font></div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
    <div style="font-size: 10pt; text-align: justify; text-indent: 72pt;"><font style="font-family: 'Times New Roman';">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Termination for Executive&#8217;s Permanent Disability</u>. To the extent permissible under applicable law, in the event
        Executive becomes permanently disabled during employment with the Company, the Company may terminate this Agreement by giving thirty (30) days' notice to Executive of its intent to terminate, and unless Executive resumes performance of the duties
        set forth in Section 3 within five (5) days of the date of the notice and continues performance for the remainder of the notice period, this Agreement shall terminate at the end of the thirty (30) day period. For purposes of this Agreement,
        &#8220;permanently disabled&#8221; shall mean if Executive is considered totally disabled under any group disability plan maintained by the Company and in effect at that time, or in the absence of any such plan, under applicable Social Security regulations, to
        the extent not inconsistent with applicable law. In the event of any dispute under this Section 5(d), Executive shall submit to a physical examination by a licensed physician mutually satisfactory to the Company and Executive, the cost of such
        examination to be paid by the Company, and the determination of such physician shall be determinative. In the event the Executive is terminated pursuant to this Section 5(d), Executive will be entitled to the Accrued Obligations and the Non-CIC
        Termination Compensation, subject to the terms, conditions and restrictions set forth in Section 5(c)(ii).</font></div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">7</font></div>
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0px; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0); clear: both;"></div>
    </div>
    <div style="font-size: 10pt; text-align: justify; text-indent: 72pt;"><font style="font-family: 'Times New Roman';">(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Termination Due to Executive&#8217;s Death</u>. This Agreement will terminate immediately upon Executive&#8217;s death and the
        Company shall not have any further liability or obligation to Executive, Executive&#8217;s executors, heirs, assigns or any other person claiming under or through Executive&#8217;s estate, except that Executive&#8217;s estate shall receive any Accrued Obligations.
        In addition, Executive&#8217;s estate shall be entitled to accelerated vesting of the portion of the Option Grant that would have otherwise vested during the nine (9) month period following such termination.</font></div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt;"><br>
      </font> </div>
    <div style="font-size: 10pt; text-align: justify; text-indent: 72pt;"><font style="font-family: 'Times New Roman';">(f)&#160;&#160;&#160;&#160;&#160; <u>Continuing Obligations</u>. The obligations imposed on Executive with respect to the surviving non-competition,
        non-solicitation, confidentiality, non-disclosure and assignment of rights to inventions or developments in this Agreement or any other agreement executed by the Parties shall continue, notwithstanding the termination of the employment relationship
        between the Parties and regardless of the reason for such termination.</font></div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">6.</font><font style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Company










          Property. </font>All correspondence, records, documents, software, promotional materials, and other Company property, including all copies, which come into Executive&#8217;s possession by, through or in the course of Executive&#8217;s employment, regardless
        of the source and whether created by Executive, are the sole and exclusive property of the Company, and immediately upon the termination of Executive&#8217;s employment, or at any time the Company shall request, Executive shall return to the Company all
        such property of the Company, without retaining any copies, summaries or excerpts of any kind or in any format whatsoever. Executive shall not destroy any Company property, such as by deleting electronic mail or other files, other than in the
        normal course of Executive&#8217;s employment. Executive further agrees that should Executive discover any Company property or Confidential Information in Executive&#8217;s possession after the return of such property has been requested, Executive agrees to
        return it promptly to Company without retaining copies, summaries or excerpts of any kind or in any format whatsoever.</font></div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
    <div>
      <div style="font-weight: bold; margin-left: 36pt; font-size: 10pt;">7.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Non-Competition and Non-Solicitation.</div>
    </div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
    <div style="font-size: 10pt; text-align: justify; text-indent: 72pt;"><font style="font-family: 'Times New Roman';">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Executive agrees and acknowledges that, in connection with Executive&#8217;s employment with the Company, Executive will be
        provided with access to and become familiar with confidential and proprietary information and trade secrets belonging to the Company and its affiliates. Accordingly, in consideration of Executive&#8217;s employment with the Company pursuant to this
        Agreement, and other good and valuable consideration, the receipt of which is hereby acknowledged, Executive agrees that, while Executive is in the employ of the Company and/or any of its affiliates, Executive shall not, either on Executive&#8217;s own
        behalf or on behalf of any third party, except on behalf of the Company or one of its affiliates, directly or indirectly:</font></div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
    <div style="margin: 0px 0px 0px 0px; text-align: justify; text-indent: 108pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;engage directly or indirectly in the Business (as defined below) anywhere in the Restricted
        Territory (as defined below) or directly or indirectly be or become an officer, director, stockholder, owner, affiliate, partner, member, investor, joint venture, employee, agent, representative, consultant, lender, advisor, manager of, for or to,
        or otherwise be or become associated with or acquire or hold (of record, beneficially or otherwise) any direct or indirect interest in, any business or enterprise engaged directly or indirectly in the Business (as defined below) anywhere in the
        Restricted Territory (as defined below). As used herein, (A) the term &#8220;<font style="font-weight: bold; font-style: italic;">Business</font>&#8221; shall mean the business of development and manufacturing of a cytokine immunotherapy (related to or derived
        from human source material) for cancer treatment and RNA based gene therapy and editing of MSC, HSC, TILs, T-Cells, and in vivo and (B) the term &#8220;<font style="font-weight: bold; font-style: italic;">Restricted Territory</font>&#8221; shall mean
        worldwide. The foregoing restriction shall not be construed to</font><font style="font-size: 10pt;"> prohibit the ownership by Executive as a passive investment of shares of capital stock of a publicly- held corporation that engages in the Business
        if (x) such shares are actively traded on an established national securities market in the United States or any other foreign securities exchange, (y) the number of shares of such corporation&#8217;s capital stock that are owned beneficially (directly or
        indirectly) by Executive and the number of shares of such corporation&#8217;s capital stock that are owned beneficially (directly or indirectly) by Executive&#8217;s affiliates collectively represent less than one percent (1%) of the total number of shares of
        such corporation&#8217;s capital stock outstanding, and<font style="font-family: 'Times New Roman';"> (z) neither Executive nor any affiliate of Executive is otherwise associated directly or indirectly with such corporation or with any affiliate of such
          corporation; or</font></font></div>
    <div style="text-align: justify; margin-left: 5pt; font-size: 10pt;"><font style="font-family: 'Times New Roman';"> <br>
      </font></div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">8</font></div>
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0px; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0); clear: both;"></div>
    </div>
    <div style="font-size: 10pt; text-align: justify; text-indent: 108pt;"><font style="font-family: 'Times New Roman';">(ii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;attempt in any manner to solicit, induce or attempt to induce any business, enterprise, or individual who has a business
        relationship with the Company (including any customer, licensee, supplier, manufacturer or vendor) (x) to cease doing business with the Company or any of its affiliates, (y) to diminish or materially alter in a manner harmful to the Company or any
        of its affiliates, or any of their affiliates such business, enterprise, or individual&#8217;s relationship with the Company or any of its affiliates, or (z) to purchase, contract for or receive any products or services from any business or enterprise
        (other than the Company or any of its affiliates) that engages in the Business anywhere within the Restricted Territory.</font></div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
    <div style="font-size: 10pt; text-align: justify; text-indent: 72pt;"><font style="font-family: 'Times New Roman';">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Executive agrees and acknowledges that for one (1) year period following the end of Executive&#8217;s employment for any reason,
        Executive shall not, either on Executive&#8217;s own behalf or on behalf of any third party (A) directly or indirectly hire any employee, independent contractor, or consultant or any person who was an employee, independent contractor, or consultant of
        the Company within the preceding six (6) months, or (B) directly or indirectly encourage, induce, attempt to induce, solicit or attempt to solicit (on Executive&#8217;s own behalf or on behalf of any other business, enterprise, or individual) any
        employee, independent contractor, or consultant to leave or curtail his or her employment or engagement with the Company or any of its affiliates; provided, however, that notwithstanding the foregoing, this Section 7(b) shall not prevent Executive
        from undertaking general solicitations of employment not targeted at employees, independent contractors, or consultants of the Company or any of its affiliates (so long as Executive does not, directly or indirectly, hire any such employee,
        independent contractor, or consultant). If, during the one (1) year period following the end of Executive&#8217;s employment for any reason, Executive wishes to directly or indirectly hire a consultant or any person who was a consultant of the Company
        within the preceding six (6) months, Executive must seek written permission from the Company&#8217;s CEO, which permission will not be unreasonably withheld.</font></div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
    <div style="font-size: 10pt; text-align: justify; text-indent: 72pt;"><font style="font-family: 'Times New Roman';">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Parties agree that the relevant public policy aspects of post-employment restrictive covenants have been discussed, and
        that every effort has been made to limit the restrictions placed upon Executive to those that are reasonable and necessary to protect the Company&#8217;s legitimate interests. Executive acknowledges that, based upon Executive&#8217;s education, experience, and
        training, the restrictions set forth in this Section 7 will not prevent Executive from earning a livelihood and supporting Executive and Executive&#8217;s family during the relevant time period. Executive further acknowledges that, because the Company
        markets its products and services throughout the Restricted Territory, a more narrow geographic limitation on the restrictive covenants set forth above would not adequately protect the Company&#8217;s legitimate business interests.</font></div>
    <div style="text-align: justify; text-indent: 72pt; margin-left: 5pt; font-size: 10pt;"><font style="font-family: 'Times New Roman';"> <br>
      </font></div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">9</font></div>
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0px; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0); clear: both;"></div>
    </div>
    <div style="font-size: 10pt; text-align: justify; text-indent: 72pt;"><font style="font-family: 'Times New Roman';">(d)&#160;&#160;&#160;&#160;&#160;&#160; If any restriction set forth in this Section 7 is found by any court of competent jurisdiction or arbitrator to be
        unenforceable because it extends for too long a period of time or over too great a range of activities or geographic area, it shall be interpreted to extend over the maximum period of time, range of activities or geographic area as to which it may
        be enforceable.</font></div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
    <div style="font-size: 10pt; text-align: justify; text-indent: 72pt;"><font style="font-family: 'Times New Roman';">(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The restrictions contained in Section 7 are necessary for the protection of the business and goodwill of the Company and/or
        its affiliates and are considered by Executive to be reasonable for such purposes. Executive agrees that any material breach of Section 7 will result in irreparable harm and damage to the Company and/or its affiliates that cannot be adequately
        compensated by a monetary award. Accordingly, it is expressly agreed that in addition to all other remedies available at law or in equity (including, without limitation, money damages from Executive), the Company and/or such affiliate may be
        entitled to a temporary restraining order, preliminary injunction or such other form of injunctive or equitable relief as may be issued by any court of competent jurisdiction or arbitrator, based on the discretion of the judge or arbitrator, to
        restrain or enjoin Executive from breaching any such covenant or provision or to specifically enforce the provisions hereof, without the need to post any bond or other security.</font></div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
    <div style="font-size: 10pt; text-align: justify; text-indent: 72pt;"><font style="font-family: 'Times New Roman';">(f)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The existence of a claim, charge, or cause of action by Executive against the Company shall not constitute a defense to the
        enforcement by the Company of the foregoing restrictive covenants.</font></div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
    <div style="font-size: 10pt; text-align: justify; text-indent: 72pt;"><font style="font-family: 'Times New Roman';">(g)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The provisions of this Section 7 shall apply regardless of the reason for the termination of Executive&#8217;s employment.</font></div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">8.</font><font style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Non-Circumvention/Non-Interference.










        </font>Executive acknowledges and agrees that during the Employment Period, other than acting on behalf of the Company in his capacity as an employee of the Company, Executive shall not, and shall not authorize or permit any of Executive&#8217;s
        Representatives to, directly or indirectly, interfere, discuss, contact, initiate, or engage, encourage, solicit, initiate, facilitate or continue inquiries to any third parties concerning any business opportunities related to the Company. It is
        understood that, during the Employment Period, without previous written consent from the Company, the Executive will not enter, either directly or indirectly, into any discussions, solicit or accept offers, enter into any agreements, conduct
        negotiations with or otherwise engage in any other independent communications unrelated to the Company&#8217;s business with: any third party to whom Executive was introduced to by any member, shareholder, officer, director, employee, agent, customer,
        supplier, vendor, or other representative of the Company, Factor Bioscience, or Novellus, Inc.; any third party to whom Executive was informed of by any member, shareholder, officer, director, employee, agent, customer, supplier, vendor, or other
        representative of Company, Factor Bioscience, or Novellus, Inc. or any employee, financial partner, investor, contractor of the Company. For purposes of this Agreement, "Representatives" means, as to Company, its affiliates, and respective
        consultants (including attorneys, financial advisors and accountants). Further, after termination of Executive&#8217;s employment with the Company, Executive will not take any action or omit to take an action intended to interfere with existing
        contractual and or business relationships with the Company in a manner prohibited by law.</font></div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">10</font></div>
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0px; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0); clear: both;"></div>
    </div>
    <div>
      <div style="font-weight: bold; margin-left: 36pt; font-size: 10pt;">9.<font style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Protection of Confidential Information.</div>
    </div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
    <div style="font-size: 10pt; text-align: justify; text-indent: 72pt;"><font style="font-family: 'Times New Roman';">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Executive agrees that all information, whether or not in writing, relating to the business, technical or financial affairs
        of the Company and that is generally understood in the industry as being confidential and/or proprietary information, is the exclusive property of the Company. Executive agrees to hold in a fiduciary capacity for the sole benefit of the Company all
        secret, confidential and/or proprietary information, knowledge, and data, including trade secrets, relating to the Company or any of its affiliates obtained during Executive&#8217;s employment with the Company or any of its predecessors or affiliates,
        including but not limited to any trade secrets, confidential or secret designs, website technologies, content, processes, formulae, plans, manuals, devices, machines, know-how (including without limitation the manufacturing of IRX-2), methods,
        compositions, ideas, improvements, financial and marketing information, costs, pricing, sales, sales volume, salaries, methods and proposals, customer and prospective customer lists, customer identities, customer volume, or customer contact
        information, identity of key personnel in the employ of customers and prospective customers, amount or kind of customer&#8217;s purchases from the Companies or their affiliates, manufacturer lists, manufacturer identities, manufacturer volume, or
        manufacturer contact information, identity of key personnel in the employ of manufacturers, amount or kind of the Companies&#8217; or their affiliates&#8217; purchases from manufacturers, system documentation, hardware, engineering and configuration
        information, computer programs, source and object codes (whether or not patented, patentable, copyrighted or copyrightable), related software development information, inventions or other confidential or proprietary information (including without
        limitation information relating to IRX-2 and its intellectual property that has not yet issued) belonging to the Companies or their affiliates or directly or indirectly relating to the Companies&#8217; or their affiliates&#8217; business and affairs (&#8220;<font style="font-weight: bold; font-style: italic;">Confidential Information</font>&#8221;). Executive agrees that Executive will not at any time, either during the Employment Period or the Confidentiality Period (as defined below), disclose to anyone any
        Confidential Information, or utilize such Confidential Information for Executive&#8217;s own benefit, or for the benefit of third parties without written approval by an officer of the Company. For purposes of this section, the &#8220;<font style="font-weight: bold; font-style: italic;">Confidentiality Period</font>&#8221; means so long as such information, data, or material remains confidential. Executive further agrees that all memoranda, notes, records, data, schematics, sketches, computer programs,
        prototypes, or written, photographic, magnetic or other documents or tangible objects compiled by Executive or made available to Executive during the Employment Period concerning the business of the Company and/or its clients, including any copies
        of such materials, shall be the property of the Company and shall be delivered to the Company on the termination of Executive&#8217;s employment, or at any other time upon request of the Company.</font></div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
    <div style="font-size: 10pt; text-align: justify; text-indent: 72pt;"><font style="font-family: 'Times New Roman';">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;In the event Executive is questioned by anyone not employed by the Company or by an employee of or a consultant to the
        Company not authorized to receive such information, in regard to any Confidential Information or any other secret or confidential work of the Company, or concerning any fact or circumstance relating thereto, or in the event that Executive becomes
        aware of the unauthorized use of Confidential Information by any party, whether competitive with the Company or not, Executive will promptly notify an executive officer of the Company.</font></div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">11</font></div>
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0px; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0); clear: both;"></div>
    </div>
    <div style="font-size: 10pt; text-align: justify; text-indent: 72pt;"><font style="font-family: 'Times New Roman';">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Court-Ordered Disclosure</u>. In the event that, at any time during Executive&#8217;s employment with the Company or at any
        time thereafter, Executive receives a request to disclose any Confidential Information under the terms of a subpoena or order issued by a court or by a governmental body, Executive agrees to notify the Company immediately of the existence, terms,
        and circumstances surrounding such request, to consult with the Company on the advisability of taking legally available steps to resist or narrow such request; and, if disclosure of such Confidential Information is required to prevent Executive
        from being held in contempt or subject to other penalty, to furnish only such portion of the Confidential Information as, in the written opinion of counsel satisfactory to the Company, Executive is legally compelled to disclose, and to exercise
        Executive&#8217;s best efforts to obtain an order or other reliable assurance that confidential treatment will be accorded to the disclosed Confidential Information.</font></div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
    <div style="font-size: 10pt; text-align: justify; text-indent: 72pt;"><font style="font-family: 'Times New Roman';">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Defend Trade Secrets Act</u>. Pursuant to the Defend Trade Secrets Act of 2016, Executive acknowledges that Executive
        shall not have criminal or civil liability under any federal or state trade secret law for the disclosure of a trade secret that (A) is made (i) in confidence to a federal, state, or local government official, either directly or indirectly, or to
        an attorney and</font> (ii) solely for the purpose of reporting or investigating a suspected violation of law; or (B) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal. In addition,
      if Executive files a demand for arbitration alleging retaliation by the Company for reporting a suspected violation of law, Executive may disclose the trade secret to Executive&#8217;s attorney and may use the trade secret information in the arbitration
      proceeding, if Executive (X) files any document containing the trade secret under seal and (Y) does not disclose the trade secret, except pursuant to an order of the arbitrator. </div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
    <div>
      <div style="font-weight: bold; margin-left: 36pt; font-size: 10pt;">10.<font style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Intellectual Property.</div>
    </div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
    <div style="font-size: 10pt; text-align: justify; text-indent: 72pt;"><font style="font-family: 'Times New Roman';">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Disclosure of Inventions</u>. Executive will promptly disclose in confidence to the Company all inventions, improvements,
        processes, products, designs, original works of authorship, formulas, processes, compositions of matter, computer software programs, Internet products and services, e-commerce products and services, e-entertainment products and services, databases,
        mask works, trade secrets, product improvements, product ideas, new products, discoveries, methods, software, uniform resource locators or proposed uniform resource locators (&#8220;<font style="font-weight: bold; font-style: italic;">URLs</font>&#8221;),
        domain names or proposed domain names, any trade names, trademarks or slogans, which may or may not be subject to or able to be patented, copyrighted, registered, or otherwise protected by law (the &#8220;<font style="font-weight: bold; font-style: italic;">Inventions</font>&#8221;) that Executive makes, conceives or first reduces to practice or creates, either alone or jointly with others, during the Employment Period, whether or not in the course of Executive&#8217;s employment (i) that result from
        any work performed by the Executive for the Company; (ii) that are developed from using the Company's equipment, supplies, facilities or trade secret information; or (iii) that relate at the time of conception or reduction to practice of the
        invention to the Company's business, or actual or demonstrably anticipated research or development of the Company. The requirements of this Section 10(a) shall not apply to any Inventions that qualify fully under the provisions of California Labor
        Code section 2870 (the terms of which are set forth on <u>Addendum B</u> to this Agreement), specifically, any Invention that Executive developed entirely on Executive&#8217;s own time without using the Employer&#8217;s equipment, supplies, facilities, or
        trade secret information except for those Inventions that either (i) relate at the time of conception or reduction to practice of the Invention to the Employer&#8217;s business, or Employer&#8217;s actual or demonstrably anticipated research or development; or
        (ii) result from any work performed by Executive for Employer. Executive shall bear the full burden of proving to the Employer that an Invention qualifies fully under California Labor Code section 2870. The foregoing requirements of Section 10(a)
        apply, and whether or not such Inventions are patentable, copyrightable or able to be protected as trade secrets, or otherwise able to be registered or protected by law. Executive has provided a list of prior Inventions as <u>Addendum C</u>, which
        will not be subject to the provisions of this Section 10.</font></div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">12</font></div>
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0px; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0); clear: both;"></div>
    </div>
    <div style="font-size: 10pt; text-align: justify; text-indent: 72pt;"><font style="font-family: 'Times New Roman';">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Assignment of Company Inventions; Work for Hire</u>. Executive agrees that all Inventions that (i) are developed using
        equipment, supplies, facilities or trade secrets of the Company, (ii) result from work performed by Executive for the Company, or (iii) relate to the Company&#8217;s business or current or anticipated research and development (the &#8220;<font style="font-weight: bold; font-style: italic;">Company Inventions</font>&#8221;), will be the sole and exclusive property of the Company and the Executive hereby agrees to irrevocably assign to the Company any such Company Inventions. Executive further
        acknowledges and agrees that any copyrightable works prepared by Executive within the scope of Executive&#8217;s employment are &#8220;works for hire&#8221; under the Copyright Act and that the Company will be considered the author and owner of such copyrightable
        works from the moment of their creation and fixation in tangible media.</font></div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
    <div style="font-size: 10pt; text-align: justify; text-indent: 72pt;"><font style="font-family: 'Times New Roman';">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Assignment of Other Rights</u>. In addition to the foregoing assignment of Company Inventions to the Company, Executive
        hereby irrevocably transfers and assigns to the Company: (i) all worldwide patents, patent applications, copyrights, mask works, trade secrets and other intellectual property rights in any Company Invention; and (ii) any and all &#8220;Moral Rights&#8221; (as
        defined below) that Executive may have in or with respect to any Company Invention. Executive also hereby forever waives and agrees never to assert any and all Moral Rights Executive may have in or with respect to any Company Invention, even after
        termination of Executive&#8217;s work on behalf of the Company. &#8220;<font style="font-weight: bold; font-style: italic;">Moral Rights</font>&#8221; means any rights to claim authorship of an Company Invention, to object to or prevent the modification of any
        Company Invention, or to withdraw from circulation or control the publication or distribution of any Company Invention, and any similar right, existing under judicial or statutory law of any country in the world, or under any treaty, regardless of
        whether or not such right is denominated or generally referred to as a &#8220;moral right.&#8221;</font></div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
    <div style="font-size: 10pt; text-align: justify; text-indent: 72pt;"><font style="font-family: 'Times New Roman';">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Assistance</u>. Executive agrees to assist the Company in every proper way to obtain for the Company and enforce
        patents, copyrights, mask work rights, trade secret rights and other legal protections for the Company Inventions in any and all countries. Executive will execute any documents that the Company may reasonably request for use in obtaining or
        enforcing such patents, copyrights, mask work rights, trade secrets and other legal protections. Executive&#8217;s obligations under this section will continue beyond the termination of Executive&#8217;s employment with the Company, provided that the Company
        will compensate Executive at a reasonable rate after such termination for time or expenses actually spent by Executive at the Company&#8217;s request on such assistance. Executive appoints the Secretary of the Company as Executive&#8217;s attorney-in- fact to
        execute documents on Executive&#8217;s behalf for this purpose.</font></div>
    <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold; font-size: 10pt;">&#160;</div>
    <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold; text-indent: 45pt; font-size: 10pt;">11.<font style="font-family: 'Times New Roman'; font-weight: bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; Publicity; Non-disparagement. </font><font style="font-family: 'Times New Roman'; font-weight: normal;">Neither Party shall issue, without consent of the other Party, any press release or make any public announcement with respect to this Agreement or the employment relationship between them, or the ending of
        such relationship. Following the date of this Agreement and regardless of any dispute that may arise in the future, Executive agrees that Executive will not disparage, criticize or make statements which are negative, detrimental or injurious to
        Company or any of its affiliates, or any of their affiliates to any individual, company or client, including within the Company, and the Company agrees that Company employees at the Vice President level or above will not make statements on the
        Company&#8217;s behalf that disparage, criticize or make statements which are negative, detrimental or injurious to Executive. This <u>Section 11</u> does not, in any way, restrict or impede the parties hereto from exercising protected rights to the
        extent that such rights cannot be waived by agreement or from complying with any applicable law or regulation or a valid order of a court of competent jurisdiction or an authorized government agency, provided that such compliance does not exceed
        that required by the law, regulation, or order. Nothing contained herein shall prevent anyone bound by this Section 11 from providing true testimony to the extent required within any legal proceeding (or in any discovery in connection therewith) or
        investigation by a governmental authority.</font></div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal;">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">13</font></div>
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0px; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0); clear: both;"></div>
    </div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">12.</font><font style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Binding










          Agreement. </font>This Agreement shall be binding upon and inure to the benefit of the Parties hereto, their heirs, personal representatives, successors and assigns. Executive acknowledges and agrees that the Company may, in its sole discretion,
        assign this Agreement (i) to an affiliate of the Company at any time, or (ii) in the event the Company is acquired, is a non-surviving party in a merger, or transfers substantially all of its assets, to the transferee or surviving company, in each
        case without being required to obtain Executive&#8217;s consent. The Parties understand that the obligations of Executive are personal and may not be assigned by him.</font></div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">13.</font><font style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;&#160;&#160;&#160;&#160; &#160;&#160; <font style="font-weight: bold;">Entire










          Agreement. </font>This Agreement contains the entire understanding of Executive and the Company with respect to employment of Executive. This Agreement may not be amended, waived, discharged or terminated orally, but only by an instrument in
        writing, specifically identified as an amendment to this Agreement, and signed by all Parties. By entering into this Agreement, Executive certifies and acknowledges that Executive has carefully read all of the provisions of this Agreement and that
        Executive voluntarily and knowingly enters into said Agreement.</font></div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">14.</font><font style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold;">Severability.










        </font>Any provision of this Agreement which is prohibited or unenforceable in any jurisdiction shall, as to such jurisdiction, be deemed severable from the remainder of this Agreement, and the remaining provisions contained in this Agreement shall
        be construed to preserve to the maximum permissible extent the intent and purposes of this Agreement.</font></div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt;"><br>
      </font> </div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">15.</font><font style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Tax










          Consequences</font>. If any payment or benefit the Executive would receive pursuant to this Agreement (<font style="font-weight: bold; font-style: italic;">&#8220;Payment&#8221;</font>) would (a) constitute a &#8220;<font style="font-weight: bold; font-style: italic;">Parachute Payment</font>&#8221; within the meaning of Section 280G of the Code, and (b) but for this sentence, be subject to the excise tax imposed by Section 4999 of the Code (the &#8220;<font style="font-weight: bold; font-style: italic;">Excise
          Tax</font>&#8221;), then such Payment shall be equal to the Reduced Amount. The &#8220;<font style="font-weight: bold; font-style: italic;">Reduced Amount</font>&#8221; shall be either (i) the largest portion of the Payment that would result in no portion of the
        Payment being subject to the Excise Tax or (ii) the largest portion, up to and including the total of the Payment, whichever amount, after taking into account all applicable federal, state and local employment taxes, income taxes, and the Excise
        Tax (all computed at the highest applicable marginal rate), results in the Executive&#8217;s receipt, on an after- tax basis, of the greatest economic benefit notwithstanding that all or some portion of the Payment may be subject to the Excise Tax. If a
        reduction in payments or benefits constituting Parachute Payments is necessary so that the Payment equals the Reduced Amount, reduction shall occur in the manner that results in the greatest economic benefit for Executive to the extent permitted by
        Section 409A of the Code, to the extent applicable, and Section 280G of the Code. Except as otherwise specifically provided in this Agreement, the Company will have no obligation to any person entitled to the benefits of this Agreement with respect
        to any tax obligation any such person incurs as a result of or attributable to this Agreement, including all supplemental agreements and employee benefits plans incorporated by reference therein, or arising from any payments made or to be made
        under this Agreement or thereunder. All determinations under this <font style="font-weight: bold;">Section 15 </font>will be made by an actuarial firm, accounting firm, law firm, or consulting firm experienced and generally recognized in 280G
        matters (the &#8220;<font style="font-weight: bold;">280G Firm</font>&#8221;) that is chosen by the Company prior to a change in ownership or control of a corporation (within the meaning of Treasury regulations under Section 280G of the Code). The 280G Firm
        shall be required to evaluate the extent to which payments are exempt from Section 280G as reasonable compensation for services rendered before or after the Change in Control. All fees and expenses of the 280G Firm shall be paid solely by the
        Company or its successor. The Company and Executive shall furnish the tax firm such information and documents as the tax firm may reasonably request in order to make its required determination. The 280G Firm will provide its calculations, together
        with detailed supporting documentation, to the Company and Executive as soon as practicable following its engagement. Any good faith determinations of the 280G Firm made hereunder will be final, binding and conclusive upon the Company and
        Executive.</font></div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">14</font></div>
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0px; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0); clear: both;"></div>
    </div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">16.</font><font style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold;">Withholding.










        </font>The Company shall have the right to withhold from any amount payable hereunder any federal, state, local and foreign taxes in order for the Company to satisfy any withholding tax obligation it may have under any applicable law or regulation.
        Notwithstanding any other provision of this Agreement, the Company does not guarantee any particular tax result for Executive with respect to any payment provided to Executive hereunder, and Executive shall be solely responsible for any taxes
        imposed on Executive with respect to any such payment.</font></div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
    <div>
      <div style="font-weight: bold; text-indent: 36pt; font-size: 10pt;">17.&#160;&#160;&#160;&#160;&#160;&#160;&#160; Section 409A.</div>
    </div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
    <div style="font-size: 10pt; text-align: justify; text-indent: 72pt;"><font style="font-family: 'Times New Roman';">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; This Agreement is intended to comply with, or otherwise be exempt from, Section 409A of the Code and any regulations and
        Treasury guidance promulgated thereunder (&#8220;<font style="font-weight: bold; font-style: italic;">Section 409A of the Code</font>&#8221;) and shall be construed and administered in accordance with such intent. Notwithstanding any other provision of this
        Agreement, payments provided under this Agreement may only be made upon an event and in a manner that complies with Section 409A of the Code or an applicable exemption. Any payments under this Agreement that may be excluded from Section 409A of the
        Code either as separation pay due to an involuntary separation from service or as a short-term deferral shall be excluded from Section 409A of the Code to the maximum extent possible. Notwithstanding the foregoing, the Company makes no
        representations that the payments and benefits provided under this Agreement comply with Section 409A of the Code and in no event shall the Company be liable for all or any portion of any taxes, penalties, interest or other expenses that may be
        incurred by the Executive on account of non-compliance with Section 409A of the Code.</font></div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
    <div style="font-size: 10pt; text-align: justify; text-indent: 72pt;"><font style="font-family: 'Times New Roman';">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;For purposes of Section 409A of the Code, the right to a series of installment payments under this Agreement shall be
        treated as a right to a series of separate payments. In no event may Executive, directly or indirectly, designate the calendar year of payment.</font></div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">15</font></div>
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0px; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0); clear: both;"></div>
    </div>
    <div style="font-size: 10pt; text-align: justify; text-indent: 72pt;"><font style="font-family: 'Times New Roman';">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;With respect to any reimbursement of expenses of, or any provision of in- kind benefits to, Executive, as specified under
        this Agreement, such reimbursement of expenses or provision of in-kind benefits shall be subject to the following conditions: (1) the expenses eligible for reimbursement or the amount of in-kind benefits provided in one taxable year shall not
        affect the expenses eligible for reimbursement or the amount of in-kind benefits provided in any other taxable year, except for any medical reimbursement arrangement providing for the reimbursement of expenses referred to in Section 105(b) of the
        Code; (2) the reimbursement of an eligible expense shall be made no later than the end of the year after the year in which such expense was incurred; and (3) the right to reimbursement or in-kind benefits shall not be subject to liquidation or
        exchange for another benefit.</font></div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
    <div style="font-size: 10pt; text-align: justify; text-indent: 72pt;"><font style="font-family: 'Times New Roman';">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;Termination of employment,&#8221; &#8220;resignation,&#8221; or words of similar import, as used in this Agreement means, for purposes of
        any payments under this Agreement that are payments of deferred compensation subject to Section 409A of the Code, Executive&#8217;s &#8220;separation from service&#8221; as defined in Section 409A of the Code.</font></div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
    <div style="font-size: 10pt; text-align: justify; text-indent: 72pt;"><font style="font-family: 'Times New Roman';">(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; If a payment obligation under this Agreement arises on account of Executive&#8217;s separation from service while Executive is a
        &#8220;specified employee&#8221; (as defined under Section 409A of the Code and determined in good faith by the Company), any payment of &#8220;deferred compensation&#8221; (as defined under Treasury Regulation Section 1.409A-1(b)(1), after giving effect to the exemptions
        in Treasury Regulation Sections 1.409A-1(b)(3) through (b)(12)) that is scheduled to be paid within six (6) months after such separation from service shall accrue without interest and shall be paid within fifteen (15) days after the end of the
        six-month period beginning on the date of such separation from service or, if earlier, within fifteen (15) days after the appointment of the personal representative or executor of Executive&#8217;s estate following Executive&#8217;s death.</font></div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">18.</font><font style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Governing










          Law. </font>This Agreement shall be governed by, and construed and enforced in accordance with, the laws of the State of Delaware, without giving effect to the principles of conflicts of law thereof that would result in the application of the
        laws of any jurisdiction other than the State of Delaware.</font></div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">19.</font><font style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold;">Notices.










        </font>Any notice provided for in this Agreement shall be provided in writing. Notices shall be effective from the date of service, if served personally on the Party to whom notice is to be given, or on the second day after mailing, if mailed by
        first class mail, postage prepaid. Notices shall be properly addressed to the Parties at their respective addresses or to such other address as either Party may later specify by notice to the other.</font></div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">16</font></div>
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0px; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0); clear: both;"></div>
    </div>
    <div>
      <div style="font-weight: bold; text-indent: 36pt; font-size: 10pt;">20.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Dispute Resolution.</div>
    </div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
    <div style="font-size: 10pt; text-align: justify; text-indent: 72pt;"><font style="font-family: 'Times New Roman';">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Executive and the Company mutually agree that any controversy or claim arising out of or relating to this Agreement or the
        employment relationship between Executive and the Company, including any dispute regarding the scope or enforceability of this arbitration provision, shall be settled by individual arbitration administered by Judicial Arbitration and Mediation
        Services (JAMS) in accordance with the JAMS Employment Arbitration Rules and Procedures in effect as of the date of this Agreement (&#8220;<u>JAMS Rules</u>&#8221;), to the extent the JAMS Rules are consistent with the terms of this provision. Judgment on the
        award may be entered in any court having jurisdiction thereof. The parties also mutually agree that, except as otherwise required by enforceable law, arbitration shall be the sole and exclusive forum for resolving such disputes (including any
        dispute with the Company, any related parties, and any of their respective employees, officers, owners or agents, who shall be third-party beneficiaries of this provision), and both parties agree that they are hereby waiving any right to have their
        disputes resolved in civil litigation by a court or jury trial, including but not limited to any disputes arising under statutes such as Title VII of the Civil Rights Act, the Age Discrimination in Employment Act, or the California Fair Employment
        and Housing Act. The arbitrator&#8217;s decisions on such matters shall be final and binding on the parties to the fullest extent permitted by law. The JAMS Rules are incorporated herein by reference, to the extent they are consistent with the terms of
        this provision, and may be found at available at https://www.jamsadr.com/rules-employment-arbitration/. The place of arbitration shall be San Diego County, California or an alternate location selected by the parties. Any arbitration hereunder shall
        be conducted only on an individual basis and not in a class, consolidated, or representative action. The Company shall pay the administrative costs and fees directly related to the arbitration, including the fees of the arbitrator. Each party shall
        otherwise bear its own respective attorneys&#8217; fees and costs, including the costs of any depositions or for expert witnesses, unless any applicable law provides otherwise to the prevailing party, in which case the arbitrator shall have the authority
        to award costs and attorneys&#8217; fees to the prevailing party in accordance with the applicable law. Neither a party nor the arbitrator may disclose the existence, content, or results of any arbitration hereunder without the prior written consent of
        both parties, unless otherwise provided by law. The parties&#8217; agreement to arbitrate does not apply to claims that, pursuant to applicable law, cannot be subject to mandatory arbitration, including claims under the Private Attorney General Act;
        provided that, in the event of a dispute regarding whether, or the extent to which, any dispute is subject to arbitration, the parties agree that no underlying dispute or any facts regarding such dispute shall be submitted to a court until and
        unless a declaratory judgment is issued by the duly appointed arbitrator that allows a dispute to proceed in court based on a claim by a party that this arbitration provision is unenforceable as a matter of law as to an asserted claim. Moreover,
        nothing in this Agreement prevents Executive from filing or prosecuting a charge with any government agency (such as the Equal Employment Opportunity Commission, or the California Department of Fair Employment and Housing) over which such agency
        has jurisdiction, or from participating in an investigation or proceeding conducted by any such agency. Any matter required to be arbitrated under this Section 20 shall be submitted to mediation in a manner agreed to by Executive and the Company.
        Executive and the Company agree to use mediation to attempt to resolve any such matter prior to filing for arbitration. Executive and the Company will select a mediator agreeable to both parties. The costs of the mediation and fees of the mediator
        will be borne entirely by the Company.</font></div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 36pt;">BY AGREEING TO ARBITRATION, THE PARTIES ACKNOWLEDGE THAT THEY WAIVE THE RIGHT TO BRING AND/OR PARTICIPATE IN ANY CLASS OR
      COLLECTIVE ACTION. THE ARBITRATOR SHALL HAVE NO POWER TO ARBITRATE ANY CLASS AND/OR COLLECTIVE CLAIMS. BY AGREEING TO ARBITRATION, THE PARTIES ACKNOWLEDGE THAT THEY ARE WAIVING THEIR STATUTORY AND COMMON LAW RIGHTS TO SEEK RELIEF IN A COURT OF LAW
      AND ARE WAIVING THEIR RIGHTS TO A TRIAL BY JURY.</div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
    <div style="font-size: 10pt; text-align: justify; text-indent: 72pt;"><font style="font-family: 'Times New Roman';">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Notwithstanding the provisions of Section 20(a), the Parties further acknowledge and agree that, due to the nature of the
        confidential information, trade secrets, and intellectual property belonging to the Company to which Executive has or will be given access, and the likelihood of significant harm that the Company would suffer in the event that such information was
        disclosed to third parties, the Company shall have the right to file suit in a court of competent jurisdiction to seek injunctive relief to prevent Executive from violating the obligations established in Sections 7, 8, 9 or 10 of this Agreement
        without first submitting the claim, controversy, or dispute to JAMS mediation or arbitration.</font></div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br>
    </div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">17</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">21.</font><font style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold;">Indemnification.










        </font>The Company shall indemnify and hold harmless Executive for any liability to any third-party incurred by reason of any act or omission performed by Executive while acting in good faith on behalf of the Company and within the scope of the
        authority of Executive pursuant to this Agreement and under the rules and policies of the Company, except that Executive must have in good faith believed that such action was in the best interest of the Company and such course of action or inaction
        must not have constituted gross negligence, fraud, willful misconduct, or breach of a fiduciary duty.</font></div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
    <div>
      <div style="font-weight: bold; text-indent: 36pt; font-size: 10pt;">22. &#160; &#160; &#160; &#160; Miscellaneous.</div>
    </div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
    <div style="font-size: 10pt; text-align: justify; text-indent: 72pt;"><font style="font-family: 'Times New Roman';">(a)&#160;&#160;&#160;&#160;&#160;&#160; <u>Compensation Recovery Policy</u>. Executive acknowledges and agrees that, to the extent the Company adopts any claw-back
        or similar policy pursuant to the Dodd-Frank Wall Street Reform and Consumer Protection Act or otherwise, and any rules and regulations promulgated thereunder, he or she shall take all action necessary or appropriate to comply with such policy
        (including, without limitation, entering into any further agreements, amendments or policies necessary or appropriate to implement and/or enforce such policy with respect to past, present and future compensation, as appropriate).</font></div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt;"><br>
      </font> </div>
    <div style="font-size: 10pt; text-align: justify; text-indent: 72pt;"><font style="font-family: 'Times New Roman';">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;No delay or omission by the Company in exercising any right under this Agreement shall operate as a waiver of that or any
        other right. A waiver or consent given by the Company on any one occasion shall be effective only in that instance and shall not be construed as a bar or waiver of any right on any other occasion.</font></div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
    <div style="font-size: 10pt; text-align: justify; text-indent: 72pt;"><font style="font-family: 'Times New Roman';">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The captions of the sections of this Agreement are for convenience of reference only and in no way define, limit or affect
        the scope or substance of any section of this Agreement.</font></div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
    <div style="font-size: 10pt; text-align: justify; text-indent: 72pt;"><font style="font-family: 'Times New Roman';">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The language in all parts of this Agreement will be construed, in all cases, according to its fair meaning, and not for or
        against either Party hereto. The Parties acknowledge that each Party and its counsel have reviewed and revised this Agreement and that the normal rule of construction to the effect that any ambiguities are to be resolved against the drafting Party
        will not be employed in the interpretation of this Agreement.</font></div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
    <div style="font-size: 10pt; text-align: justify; text-indent: 72pt;"><font style="font-family: 'Times New Roman';">(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The obligations of Company under this Agreement, including its obligation to pay the compensation provided for in this
        Agreement, are contingent upon Executive&#8217;s performance of Executive&#8217;s obligations under this Agreement.</font></div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt; font-size: 10pt;"><font style="font-family: 'Times New Roman';">(f)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;This Agreement may be executed in counterparts, each of which shall constitute an original, but all of which shall
        constitute one agreement.</font></div>
    <div style="text-align: justify; text-indent: 72pt; margin-left: 5pt; font-size: 10pt;"><font style="font-family: 'Times New Roman';"> <br>
      </font></div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: center; font-weight: bold;">[Signatures on following page]</div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">18</font></div>
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0px; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0); clear: both;"></div>
    </div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left;">IN WITNESS WHEREOF, Executive and the undersigned duly authorized representative of the Company have executed this Agreement as of the date first set forth above.</div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;">
      <table cellspacing="0" cellpadding="0" border="0" id="z5726d72af1e24945bcb0c504e21492e4" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">

          <tr>
            <td style="width: 50.00%;">
              <div>&#160;</div>
            </td>
            <td colspan="2" style="font-weight: bold;">EXECUTIVE</td>
          </tr>
          <tr>
            <td style="width: 50.00%;">
              <div>&#160;</div>
            </td>
            <td colspan="2">
              <div>&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; padding-bottom: 2px;">
              <div>&#160;</div>
            </td>
            <td colspan="2" style="border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: left; font-size: 10pt;">/s/ Andrew Jackson</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50.00%;">
              <div>&#160;</div>
            </td>
            <td colspan="2">
              <div style="text-align: left; font-size: 10pt;">Andrew Jackson</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50.00%;">
              <div>&#160;</div>
            </td>
            <td colspan="2">
              <div>&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50.00%;">
              <div>&#160;</div>
            </td>
            <td colspan="2">
              <div>
                <div style="text-align: left; font-weight: bold; font-size: 10pt;">BROOKLYN IMMUNOTHERAPEUTICS, INC</div>
              </div>
            </td>
          </tr>
          <tr>
            <td style="width: 50.00%;">
              <div>&#160;</div>
            </td>
            <td colspan="2">
              <div>&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; padding-bottom: 2px;">
              <div>&#160;</div>
            </td>
            <td style="width: 2%; padding-bottom: 2px;">By:</td>
            <td style="width: 48%; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: left; font-size: 10pt;">/s/ Howard J. Federoff</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50.00%;">
              <div>&#160;</div>
            </td>
            <td style="width: 2%;">
              <div style="text-align: left; margin-right: 55.5pt; font-size: 10pt;"><br>
              </div>
            </td>
            <td style="width: 48%;">
              <div style="text-align: left; margin-right: 55.5pt; font-size: 10pt;">Howard J. Federoff, MD, PhD</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50.00%;">
              <div>&#160;</div>
            </td>
            <td colspan="2">
              <div style="text-align: left; margin-right: 55.5pt; font-size: 10pt;"><br>
              </div>
            </td>
          </tr>
          <tr>
            <td style="width: 50.00%;">
              <div>&#160;</div>
            </td>
            <td colspan="2">
              <div style="text-align: left; margin-right: 55.5pt; font-size: 10pt;">Title: Chief Executive Officer/President</div>
            </td>
          </tr>

      </table>
    </div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br>
    </div>
    <div style="text-align: center; margin-right: 108.7pt; margin-left: 107.8pt; font-family: 'Times New Roman'; font-size: 10pt;">[<font style="font-style: italic;">Signature Page to Executive Employment Agreement</font>]</div>
    <div style="text-align: center; margin-right: 108.7pt; margin-left: 107.8pt; font-family: 'Times New Roman'; font-size: 10pt;"> <font style="font-size: 10pt;"><br>
      </font> </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0px; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0); clear: both;"></div>
    </div>
    <div style="text-align: center; margin-right: 108.65pt; margin-left: 107.8pt; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><u>ADDENDUM A</u></div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
    <div style="text-align: center; margin-right: 108.7pt; margin-left: 107.8pt; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Job Duties</div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;">Overall: </font><font style="font-family: 'Times New Roman'; font-size: 10pt;">The Chief
        Financial Officer partners with the Chief Executive Officer/President to set goals for performance and growth, frame strategic trade-offs, and facilitate decision-making; ensure alignment across the C-suite and with the Board of Directors as it
        relates to financial matters and implications for operations and programs.</font></div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable" id="z58d2d77ca180498198b245baaee81ab4">

        <tr>
          <td style="width: 23pt; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt;"><br>
            </font> </td>
          <td style="width: 17.95pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: left;">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;">Capital Raising, Strategic Finance and SEC matters: </font><font style="font-family: 'Times New Roman'; font-size: 10pt;">In partnership with the CEO, the CFO should drive the Company&#8217;s financing efforts. He/she will evaluate capital raising activities with existing and new investors as the Company will continue to raise money to
                build the clinical pipeline. He/she should partner with the CEO and the board of directors to build a long-term capital strategy and execute on the different levers that can be pulled to capitalize the Company. The CFO should also be able
                to sell the Company story to all external financial constituents &#8211; current and new investors, analysts, the financial community and other partners/vendors. Oversee the Treasury function, manage the Company&#8217;s investments. The CFO is
                responsible for SEC compliance and filings.</font></div>
          </td>
        </tr>

    </table>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable" id="zf5c50bc7359a474ba7ff01b7d87a7363">

        <tr>
          <td style="width: 23pt; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt;"><br>
            </font> </td>
          <td style="width: 17.95pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: left;">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;">Financial Oversight: </font><font style="font-family: 'Times New Roman'; font-size: 10pt;">Direct
                and oversee Company&#8217;s financial administration including the preparation of monthly financial statements, balance sheets, cash flow statements and report operational results to management, the board of directors, shareholders and any
                current or future regulatory oversight agencies. Responsible for providing analysis and forecasting, including multi-year outlooks based on alternative scenarios, including M&amp;A activities. Such information will be used to guide business
                development, financing and strategic planning. Develop budgets and forecasts for current and proposed future operations and acquisitions. Manage quarterly and annual earnings process and preparation, schedule and external resources.
                Establish appropriate internal control systems, including Sarbanes Oxley compliance.</font></div>
          </td>
        </tr>

    </table>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable" id="zd843a3dc40c84282ab8e99b86820151a">

        <tr>
          <td style="width: 23pt; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt;"><br>
            </font> </td>
          <td style="width: 17.95pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: left;">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;">Strategic Leadership: </font><font style="font-family: 'Times New Roman'; font-size: 10pt;">Serve
                as a strategic advisor to the CEO, to the broader executive leadership team and to the board of directors, in both strategic and tactical areas of the Company, especially as they intersect with Finance.</font></div>
          </td>
        </tr>

    </table>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable" id="z1602313cccd24efbadd60cd215b9f870">

        <tr>
          <td style="width: 23pt; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt;"><br>
            </font> </td>
          <td style="width: 17.95pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: left;">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;">Business Leadership</font><font style="font-family: 'Times New Roman'; font-size: 10pt;">: Lead or
                participate in business development and expansion activities, including investments, acquisitions, alliances, joint ventures, and similar activities as related to drug products. Play a broader strategic role inside of the Company. Help the
                Company&#8217;s team drive and execute the Company&#8217;s strategic vision across other functional areas as they intersect with Finance including pipeline prioritization, business development and partnership opportunities.</font></div>
          </td>
        </tr>

    </table>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable" id="z5767e85046244a0a8e738f137a984cdb">

        <tr>
          <td style="width: 23pt; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt;"><br>
            </font> </td>
          <td style="width: 17.95pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: left;">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;">Organizational Leadership</font><font style="font-family: 'Times New Roman'; font-size: 10pt;">:
                Assist Chief Executive Officer/President with fundraising, Board of Directors presentations and interactions, and similar tasks. In collaboration with the broader executive team, set the tone and develop infrastructure to support a culture
                of cross-functional partnership. Enable and motivate a high-performing team; mentor, oversee, manage, and coach colleagues, as appropriate.</font></div>
          </td>
        </tr>

    </table>
    <div> <font style="font-size: 10pt;"><br>
      </font> </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0px; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0); clear: both;"></div>
    </div>
    <!--PROfilePageNumberReset%Num%21%%%-->
    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; text-align: center;"><font style="font-family: 'Times New Roman';"><u>ADDENDUM B</u> </font></div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; text-align: center;"><font style="font-family: 'Times New Roman';"><u> <br>
        </u></font></div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; text-align: center;"><font style="font-family: 'Times New Roman';">CALIFORNIA LABOR CODE SECTION 2870</font></div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
    <div style="text-align: left; margin-left: 5pt; font-family: 'Times New Roman'; font-size: 10pt;">Section 2870 of the California Labor Code provides as follows:</div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt;"><br>
      </font> </div>
    <div style="text-align: left; text-indent: 36pt; font-size: 10pt;"><font style="font-family: 'Times New Roman';">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Any provision in an employment agreement which provides that an employee shall assign, or offer to assign, any of his or her
        rights in an invention to his or her employer shall not apply to an invention that the employee developed entirely on his or her own time without using the employer&#8217;s equipment, supplies, facilities, or trade secret information except for those
        inventions that either:</font></div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
    <div style="margin: 0px 0px 0px 77pt; text-align: left; font-size: 10pt;"><font style="font-family: 'Times New Roman';">(1)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Relate at the time of conception or reduction to practice of the invention to the employer&#8217;s business, or actual or
        demonstrably anticipated research or development of the employer; or</font></div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
    <div>
      <div style="text-indent: 72pt; font-size: 10pt;">&#160; (2)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Result from any work performed by the employee for the employer.</div>
    </div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
    <div style="text-align: left; text-indent: 36pt; font-size: 10pt;"><font style="font-family: 'Times New Roman';">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;To the extent a provision in an employment agreement purports to require an employee to assign an invention otherwise excluded
        from being required to be assigned under subdivision (a), the provision is against the public policy of this state and is unenforceable.</font></div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">21</font></div>
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0px; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0); clear: both;"></div>
    </div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; text-align: center;"><u>ADDENDUM C</u></div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; text-align: center;">LIST OF INVENTIONS</div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0px; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0); clear: both;"></div>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><u>ADDENDUM D</u></div>
    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Contingencies</div>
    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"> <br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">I, Andrew Jackson, understand and agree that my employment with the Company is contingent upon the following:</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable" id="z77a0381630e44a6c93791cce98f20cd7">

        <tr>
          <td style="width: 18pt; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt;"><br>
            </font> </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">
            <div style="font-size: 10pt;">Demonstrating satisfactory proof of identity and legal authority to work in the United States and maintaining appropriate work authorization; and</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable" id="z63ce71a110ab4f25a92887dd81e2d527">

        <tr>
          <td style="width: 18pt; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt;"><br>
            </font> </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">
            <div style="font-size: 10pt;">Satisfactory completion of a background check in the Company&#8217;s sole discretion.</div>
          </td>
        </tr>

    </table>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);" id="zc177fe6fff1c47a0bbda15ebe271accf">

        <tr>
          <td style="width: 5%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; padding-bottom: 2px;">
            <div style="text-align: left; font-size: 10pt;">Date:</div>
          </td>
          <td style="width: 47.5%; vertical-align: top; border-bottom: 2px solid black; font-family: 'Times New Roman'; font-size: 10pt;">
            <div style="text-align: left; font-size: 10pt;">May 10, 2022</div>
          </td>
          <td style="width: 47.5%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; padding-bottom: 2px;">&#160;</td>
        </tr>

    </table>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt;"><br>
      </font> </div>
    <table cellspacing="0" cellpadding="0" border="0" align="right" style="border-collapse: collapse; width: 70%; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; text-align: left;" id="z8c962869d37b43a0857a814aad21a965">

        <tr>
          <td style="width: 1%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; padding-bottom: 2px;">
            <div style="text-align: center; margin-right: 80pt; font-size: 10pt;">Signature:</div>
          </td>
          <td style="width: 40%; vertical-align: top; border-bottom: 2px solid black;">
            <div style="text-align: left; margin-right: 80pt; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-family: 'Times New Roman';">/s/ Andrew Jackson</font></div>
          </td>
          <td style="width: 29%; vertical-align: top; padding-bottom: 2px; font-size: 10pt;">&#160;</td>
        </tr>

    </table>
    <div style="font-family: 'Times New Roman'; font-size: 10pt; clear: both;">&#160;</div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt;"><br>
      </font> </div>
    <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"> </div>
  <font style="font-size: 10pt;"> <font style="font-family: 'Times New Roman';"> </font> </font>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>brhc10038309_ex10-2.htm
<DESCRIPTION>EXHIBIT 10.2
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, Inc
         Document created using EDGARfilings PROfile 8.2.0.0
         Copyright 1995 - 2022 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <font style="font-family: 'Times New Roman'; font-size: 10pt;"> </font>
  <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
  <div>
    <div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Exhibit 10.2</div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"><img src="image1.jpg"></div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br>
    </div>
    <table cellspacing="0" cellpadding="0" id="z42d99ff533b44c6baea92102f02aaa91" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

        <tr>
          <td style="width: 64.32%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>
          <td style="width: 35.68%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
            <div style="text-align: left;">May 25, 2022</div>
          </td>
        </tr>
        <tr>
          <td style="width: 64.32%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>
          <td style="width: 35.68%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 64.32%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
            <div style="text-align: left;">Howard Federoff, M.D., Ph.D</div>
          </td>
          <td style="width: 35.68%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 64.32%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
            <div style="text-align: left;">3156 SW 27<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">th</sup> Ave, unit 203</div>
          </td>
          <td style="width: 35.68%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 64.32%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
            <div style="text-align: left;">Miami, FL 33133</div>
          </td>
          <td style="width: 35.68%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>
        </tr>

    </table>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br>
    </div>
    <table cellspacing="0" cellpadding="0" id="zfc37575f2029465fa919ca73d0f8166d" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 27pt; font-family: 'Times New Roman'; font-size: 10pt;"><br>
          </td>
          <td style="width: 45pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">RE:</td>
          <td style="width: auto; vertical-align: top; text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">
            <div style="color: rgb(0, 0, 0); font-style: italic; font-weight: bold;">Separation Agreement and General Release</div>
          </td>
        </tr>

    </table>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Dear Howard:</div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The purpose of this separation agreement (the &#8220;<u>Separation Agreement</u>&#8221;) is to memorialize the terms and conditions of the termination of your
      employment with Brooklyn ImmunoTherapeutics, Inc. (the &#8220;<u>Company</u>&#8221;) and its subsidiaries and affiliates (together with the Company collectively, the &#8220;<u>Company Group</u>&#8221;), as well as that certain Executive Employment Agreement, dated April 1,
      2021, by and between you and the Company (the &#8220;<u>Employment Agreement</u>&#8221;).&#160; Capitalized terms used but not defined herein shall have the meanings ascribed thereto in the Employment Agreement.</div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Although the termination of your employment with the Company is by mutual agreement between you and the Company, the Company has agreed to provide
      you with, among others, all of the rights and benefits you would have otherwise been entitled to receive under your Employment Agreement had the termination of your employment been due to the termination by the Company without Cause, subject to the
      terms and conditions set forth herein.</div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">To ensure that your separation from the Company occurs on mutually acceptable terms, this Separation Agreement, along with the General Release of
      Claims on <u>Exhibit A</u> attached hereto and made a part hereof (the &#8220;<u>General Release</u>&#8221;), will summarize the terms and conditions surrounding your separation including, without limitation, the compensation and benefits that will be provided
      to you.</div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><u>Termination Date</u></div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The effective date of the termination of your employment, and the Employment Agreement, is <font style="font-weight: bold;">May 25, 2022</font> (&#8220;<u>Termination



        Date</u>&#8221;).</div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><u>Resignation as Officer and Director of the Company Group</u></div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">You acknowledge and agree that, effective as of the Termination Date, you will be deemed to have resigned from all positions then held as an officer
      as well as a member of any board of directors, and any committee thereto, throughout the Company Group.</div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><u>Accrued Obligations</u></div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Whether or not you choose to sign this Separation Agreement and the General Release, the Company will pay to you any (a) accrued but unpaid base salary you have earned
      through the Termination Date, (b) accrued but unused paid time off through the Termination Date and (c) any accrued but unpaid benefits provided under the Company&#8217;s employee benefit plans, subject to and in accordance with the terms of those plans,
      in each case, less applicable withholding and employment taxes, all of which shall be paid to you within thirty (30) days after the Termination Date or such other date as required under the applicable employee benefit plan.</div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">10355 Science Center Drive, Suite 150, San Diego, CA 92121 | tel: (212) 582-1199 | brooklynitx.com</div>
    <font style="color: rgb(0, 0, 0);"> </font>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><font style="color: rgb(0, 0, 0);"><br>
      </font> </div>
    <font style="color: rgb(0, 0, 0);"> </font>
    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Mailing address: 10531 4S Commons Drive, Suite 160-550, San Diego, CA 92127</div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br>
    </div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">For purposes of this Separation Agreement and the General Release, the amounts described above in this section shall be referred to as the &#8220;<u>Accrued Obligations</u>&#8221;.</div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><u>Separation Benefits</u></div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">In the event that you execute and deliver to the Company both the Separation Agreement and the General Release, and you do not revoke the General Release within the time
      period permitted by law (such period, the &#8220;<u>Revocation Period</u>&#8221; as defined below), the following shall apply (subject to any timing restrictions as may be applicable under Section 409A of the Internal Revenue Code of 1986, as amended (the &#8220;<u>Code</u>&#8221;)):</div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br>
    </div>
    <table cellspacing="0" cellpadding="0" id="zc4eb201a345144e3b6b74bb5dac21c27" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt; font-family: 'Times New Roman'; font-size: 10pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">
            <div>Commencing on the first regular payroll date immediately following the end of the Revocation Period, the Company shall continue to pay to you your annual base salary for a period of twelve (12) months thereafter (the &#8220;<u>Severance Period</u>&#8221;)




              in accordance with the Company&#8217;s normal payroll processing, for a total gross amount equal to $<font style="font-weight: bold;"><u>450,000</u>&#160;</font>(less applicable income and employment tax withholdings).</div>
          </td>
        </tr>

    </table>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br>
    </div>
    <table cellspacing="0" cellpadding="0" id="zb3a87e7620574d0db7c983950a382315" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt; font-family: 'Times New Roman'; font-size: 10pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">
            <div>The Company shall pay you an amount equal to your target bonus for 2022, specifically $<font style="font-weight: bold;"><u>225,000</u></font>, to be payable in a lump sum (less applicable withholding and employment taxes) as and when such
              bonus would have otherwise been paid had your employment not terminated (in 2023 but no later than March 15, 2023).</div>
          </td>
        </tr>

    </table>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br>
    </div>
    <table cellspacing="0" cellpadding="0" id="z69c3221ad5ed4e1e87d4cd0fd71f93bf" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt; font-family: 'Times New Roman'; font-size: 10pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">
            <div>If you (or you and your eligible dependents) timely and properly elects health insurance continuation rights under the Consolidated Omnibus Budget Reconciliation Act of 1985 (&#8220;<u>COBRA</u>&#8221;), the Company will pay the cost of the COBRA
              premiums until the earlier of (i) the last day of the Severance Period<font style="font-weight: bold;">&#160;</font>or (ii) the termination of your rights under COBRA; provided, for the avoidance of doubt, that such covered dependents participated
              in the Company&#8217;s health plans prior to such termination, and provided, further, that if at any time the Company determines that its payment of your (or your eligible dependents&#8217;) premiums would result in a violation of law, then in lieu of
              providing the premiums described above, the Company will instead pay you a fully taxable monthly cash payment in an amount equal to the applicable premiums for such month, with such monthly payment being made on the last day of each month for
              the remainder of the Severance Period.</div>
          </td>
        </tr>

    </table>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br>
    </div>
    <table cellspacing="0" cellpadding="0" id="z58a060375bfe4f138e5322718da53485" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt; font-family: 'Times New Roman'; font-size: 10pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">
            <div>With respect to your Time-Based Option, that portion of such option that would have vested during the Severance Period had your employment not terminated, specifically with respect to <font style="font-weight: bold;"><u>656,976</u></font>
              shares (the &#8220;<u>Accelerated Time-Based Option Portion</u>&#8221;), shall become immediately vested as of the Termination Date.&#160; In addition, the vested portion of the Time-Based Option (which, as of the Termination Date, is <font style="font-weight: bold;"><u>711,727</u></font> shares), including the Accelerated Time-Based Option Portion described herein (collectively, <font style="font-weight: bold;"><u>1,259,212</u></font> shares) shall be eligible to be
              exercised for a period of thirty-six (36) months after the Termination Date.&#160;&#160; For the avoidance of doubt, any portion of the Time-Based Option that is unvested as of the Termination Date, after taking into account the Accelerated Time-Based
              Option Portion, shall be immediately forfeited as of the Termination Date, which is specifically with respect to <font style="font-weight: bold;"><u>1,368,703</u></font> shares.</div>
          </td>
        </tr>

    </table>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br>
    </div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <table cellspacing="0" cellpadding="0" id="zefd57ff32c214ee4bfd9503e4bd3f263" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt; font-family: 'Times New Roman'; font-size: 10pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">
            <div>With respect to your Milestone Option, 25/36<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">th</sup> of such option, specifically with respect to <font style="font-weight: bold;"><u>414,759</u></font> shares (the &#8220;<u>Accelerated Milestone Option Portion</u>&#8221;), shall become
              immediately vested as of the Termination Date.&#160; In addition, the vested portion of the Milestone Option, including the Accelerated Milestone Option Portion described herein (collectively, <font style="font-weight: bold;"><u>414,759</u></font>
              shares) shall be eligible to be exercised for a period of thirty-six (36) months after the Termination Date.&#160; For the avoidance of doubt, any portion of the Milestone Option that is unvested as of the Termination Date, after taking into
              account the Accelerated Time-Based Option Portion, shall be immediately forfeited as of the Termination Date, which is specifically with respect to <font style="font-weight: bold;"><u>182,494</u></font> shares.</div>
          </td>
        </tr>

    </table>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br>
    </div>
    <table cellspacing="0" cellpadding="0" id="z96685f2d08274325b7f6971abb23755e" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt; font-family: 'Times New Roman'; font-size: 10pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">
            <div>With respect to your stock options granted to you on March 11, 2022 (the &#8220;<u>2022 Option</u>&#8221;), that portion of such option that would have vested during the Severance Period had your employment not terminated, specifically with respect to
              <font style="font-weight: bold;"><u>137,900</u></font> shares (the &#8220;<u>Accelerated 2022 Option Portion</u>&#8221;), shall become immediately vested as of the Termination Date.&#160; In addition, the vested portion of the 2022 Option (which, as of the
              Termination Date, is <font style="font-weight: bold;"><u>22,983</u></font> shares), including the Accelerated 2022 Option Portion described herein (collectively, <font style="font-weight: bold;"><u>160,883</u></font> shares) shall be
              eligible to be exercised for a period of thirty-six (36) months after the Termination Date.&#160; For the avoidance of doubt, any portion of the 2022 Option that is unvested as of the Termination Date, after taking into account the Accelerated
              2022 Option Portion, shall be immediately forfeited as of the Termination Date, which is specifically with respect to <font style="font-weight: bold;"><u>252,817</u></font> shares.</div>
          </td>
        </tr>

    </table>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br>
    </div>
    <table cellspacing="0" cellpadding="0" id="zfe50eb670bdd477bbdbae509bef49e3e" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt; font-family: 'Times New Roman'; font-size: 10pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">
            <div>With respect to your performance-based restricted stock units granted to you on March 11, 2022 (the &#8220;<u>2022 PSUs</u>&#8221;), all of the performance RSUs thereunder shall immediately be forfeited back to the Company effective as of the
              Terminate Date.&#160;&#160; In connection with this forfeiture, the Company will pay you a one-time cash payment of $<font style="font-weight: bold;"><u>130,347</u></font> (the &#8220;<u>Special Bonus</u>&#8221;), which represents the value you would have received
              if you were entitled to receive a settlement of a pro rata portion of the performance RSUs (based on the number of full months from the date of grant to the end of the Severance Period, or 14 months and, therefore, 160,922 shares) assuming
              the performance metrics were waived and assuming the current per share value is $.81.&#160; The Special Bonus will be paid to you in a lump sum, less applicable income and employment tax withholdings, within thirty (30) days of the Termination
              Date.</div>
          </td>
        </tr>

    </table>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">For purposes of this Separation Agreement and the General Release, the benefits described above in this section shall be referred to as the &#8220;<u>Separation Benefits</u>&#8221;.</div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">You acknowledge and agree that as of the Termination Date, this Separation Agreement and General Release shall supersede and replace all benefits, rights and obligations
      in connection with your employment with the Company Group.&#160; Accordingly, you further acknowledge and agree that this Separation Agreement and the General Release sets forth all compensation and benefits to which you are entitled and shall be paid to
      you in full satisfaction thereof, in connection with your employment with the Company Group.</div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">You also acknowledge and agree that the Separation Benefits to be paid under this Agreement is due solely from the Company and that Insperity PEO Services, L.P. (&#8220;<u>Insperity</u>&#8221;),



      the professional employer organization retained by the Company, has no obligation to pay the Severance benefits, even though its payment may be processed through Insperity.</div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br>
    </div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><u>Integration of Employment Agreement; Survival of Certain Provisions</u></div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">As of the Termination Date, you acknowledge and agree that this Separation Agreement shall supersede and replace the Employment Agreement <u>other than</u> the
      following provisions under the Employment Agreement (collectively, the &#8220;<u>Survival Provisions</u>&#8221;): Section 6 (Company Property) provided you will be entitled to keep and not obligated to return to the Company your work laptop so long as all of the
      Company property, documents and/or confidential information are removed from such laptop, Sections 7(a)(ii) and (iii) (Non-Solicitation) provided that those individuals listed on Appendix 1 attached hereto shall be exempt from such non-solicit
      prohibition, Section 8 (Non-Circumvention/Non-Interference), Section 9 (Protection of Confidential Information), Section 10 (Intellectual Property), Section 11 (Publicity; Non-disparagement) and Section 20 (Dispute Resolution), <u>which shall remain
        in full force and effect</u>.&#160; Accordingly, you further acknowledge and agree that (i) this Separation Agreement sets forth all compensation and benefits to which you are entitled under your Employment Agreement; and (ii) in the event that you
      breach any of the Survival Provisions, the Separation Benefits shall cease immediately and you will no longer be entitled to such benefits.</div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><u>Release Of Claims Against The Company Group</u></div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">In exchange for and as a condition to receiving the Separation Benefits, you shall knowingly and willingly release the Company Group from any kind of claim you have
      arising out of or related to your employment, the Employment Agreement and/or the termination of your employment with the Company Group by executing the General Release attached hereto as <u>Exhibit A</u>.</div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">You will be required to execute the General Release, and therefore agree to be bound by
        the terms and conditions thereof, no earlier than the Termination Date but no later than thirty (30) days after such Termination Date</font><font style="font-family: 'Times New Roman'; font-size: 10pt;">.</font></div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><u>Non-Disparagement; Cooperation/Assistance; Public Announcement</u></div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Mutual Non-Disparagement</u>: Each party hereto agrees that, except as permitted or required by
        applicable law, it or you will not directly or indirectly: (i) disparage or say or write negative things about the other party or their officers, directors, agents, or employees; or (ii) initiate or participate in any discussion or communication
        that reflects negatively on the other party and their officers, directors, agents, or employees.&#160; A disparaging or negative statement is any communication, oral or written, which would tend to cause the recipient of the communication to question
        the business condition, integrity, competence, fairness, or good character of the person or entity to whom the communication relates.</font></div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">The foregoing provision and all other provisions herein do not restrict any party hereto from cooperating with any government investigation or testifying if so required
      by subpoena or as otherwise required by law.&#160; Each party hereby represents and agrees that it or you shall not now or ever in the future authorize, verbally, in writing or electronically, any formal public statement that is disparaging, derogatory or
      otherwise inflammatory about the other party to any third party, and that it or you have not and will not make or solicit any formal public comments, statements or the like that may be considered derogatory or detrimental to the other party&#8217;s good
      name and business reputation.</div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br>
    </div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Cooperation and Assistance</u>: Upon reasonable notice and at reasonable times, you agree to assist and
        cooperate with the Company, by telephone or video conference or otherwise, concerning business or legal related matters about which you possess relevant knowledge or information.&#160; Such cooperation shall only be provided at the Company's specific
        request and will include, but not be limited to, assisting or advising the Company with respect to any business-related matters or any actual or threatened legal action (including testifying in depositions, hearings, and/or trials) about which you
        possess relevant knowledge or information. In addition, you agree to promptly inform the Company if any person or entity contacts you in an effort to obtain information about the Company.&#160; The Company agrees to reimburse you for all reasonable and
        necessary costs and expenses incurred in connection with such cooperation.</font></div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Public Announcement</u>: Prior to the Company making any written public announcements or filings
        announcing your departure from the Company, you will be afforded the opportunity to review such public announcements or filings and the Company shall consider, in good faith, any comments you may have thereto and incorporate therein those the
        Company, within its discretion, determines reasonable and appropriate.</font></div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><u>Agreement Preparation and Negotiation Fees</u></div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Upon submission of invoices and other applicable documentation reasonably requested by the Company, the Company shall reimburse you for reasonable attorneys&#8217; fees and
      costs incurred by you in connection with the preparation and negotiation of this Separation Agreement and General Release, up to a maximum amount of $5,000.</div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><u>Severability; Entire Agreement; No Oral Modifications; No Waivers</u></div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">If a court of competent jurisdiction determines that any of the provisions of this Agreement are invalid or legally unenforceable, all other provisions of this Agreement
      shall not be affected and are still enforceable. This Separation Agreement and the General Release are intended to be a single integrated contract expressing our entire understanding regarding the subjects it addresses.&#160; As such, it supersedes all
      oral and written agreements and discussions that occurred before the time you sign each of them except as to any obligations you may owe to the Company Group as described in the &#8220;<font style="font-style: italic;">Integration of Employment Agreement;
        Survival of Certain Provisions</font>&#8221; section above that remain in effect.&#160; This Separation Agreement and the General Release may be amended or modified only by an agreement in writing signed by you and countersigned by an executive officer of the
      Company.&#160; The failure by the Company or you (i) to declare a breach, or (ii) to otherwise assert rights under this Agreement shall not be construed as a waiver of any of rights under this Separation Agreement and the General Release.&#160; This Separation
      Agreement and the General Release may be executed and delivered (including by facsimile or other electronic transmission) in one or more counterparts, and by the different parties hereto in separate counterparts, each of which when executed shall be
      deemed to be an original, but all of which taken together shall constitute one and the same instrument.</div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br>
    </div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><u>Governing Law; Venue; Waiver of Jury Trial</u></div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">This Separation Agreement and the General Release <font style="color: rgb(0, 0, 0);">shall be governed by the laws of the State of New York applicable to contracts
        executed and performed within that State and without respect to conflict of laws principles.&#160; The parties hereto irrevocably and unconditionally (i) agree that any suit, action or legal proceeding arising out of or relating to </font>this
      Agreement <font style="color: rgb(0, 0, 0);">shall be brought in the courts of record of the State of New York or the court of the United States, District of New York; and (ii) consent to the jurisdiction of each such court in any suit, action or
        proceeding.&#160; </font><font style="font-weight: bold; color: rgb(0, 0, 0);">THE PARTIES HEREBY IRREVOCABLY WAIVE THEIR RIGHT TO A JURY TRIAL </font><font style="font-weight: bold;">WITH RESPECT TO ANY LITIGATION DIRECTLY OR INDIRECTLY ARISING OUT
        OF, UNDER OR IN CONNECTION WITH THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED BY THIS SEPARATION AGREEMENT AND GENERAL RELEASE</font><font style="font-weight: bold; color: rgb(0, 0, 0);">.</font></div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><u>Acknowledgements and Certifications</u></div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">You acknowledge and certify that:</div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br>
    </div>
    <table cellspacing="0" cellpadding="0" id="zbeabf9719ab8461dbd69026add562635" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt; font-family: 'Times New Roman'; font-size: 10pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">
            <div>you have read and you understand all of the terms of this Separation Agreement and the General Release on <font style="font-weight: bold;"><u>Exhibit A</u></font>, and are not relying on any representation or statement, written or oral,
              not set forth in this Separation Agreement and the General Release;</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" id="z6a1380f8fc164b3f8892ba4b0ca1cd8d" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt; font-family: 'Times New Roman'; font-size: 10pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">
            <div>you are signing this Separation Agreement, and shall sign the General Release, knowingly and voluntarily;</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" id="z2809e3706e9a46b6abd79336335cbe6a" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt; font-family: 'Times New Roman'; font-size: 10pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">
            <div>you have been advised to consult with an attorney before signing this Separation Agreement and the General Release;</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" id="zc07cc49fade042499d24d506493ac60d" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt; font-family: 'Times New Roman'; font-size: 10pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">
            <div>you have the right to consider the terms of this Separation Agreement and the General Release for 21 days; however, you do not have to take all 21 days to consider it, and if you take fewer than 21 days to review this Separation Agreement
              and the General Release, you expressly waive any and all rights to consider this Separation Agreement and the General Release for the balance of the 21-day review period; and</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" id="z8aa398b999d5435793105e0f840eb1d6" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt; font-family: 'Times New Roman'; font-size: 10pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">
            <div>the General Release includes a release of any claim you might have under the ADEA (the &#8220;<u>ADEA Claims</u>&#8221;).&#160; For seven (7) days after signing the General Release, you have the right to revoke your release of ADEA Claims (the &#8220;<u>Revocation




                Period</u>&#8221;).&#160; To revoke your release of ADEA Claims, the revocation or rescission must be in writing and must be delivered by hand or sent by certified mail, return receipt requested, postmarked within the seven (7) day period, and
              properly addressed to the Chairman of the Company at 10355 Science Center Drive, Suite 150, San Diego, CA 92121. Revoking your release of ADEA Claims shall result in the invalidation of this Separation Agreement, in its entirety, as of such
              revocation date; and</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" id="zd18612b28b1442f2bd071a7071c2b75f" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt; font-family: 'Times New Roman'; font-size: 10pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">
            <div>you and the Company and Parent each agree that any changes that have been made to this Separation Agreement and the General Release from the versions originally presented to you do not extend the 21-day period you have been given to
              consider this Separation Agreement and the General Release, whether those changes are deemed material or non-material.</div>
          </td>
        </tr>

    </table>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br>
    </div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">IF YOU SIGN THIS DOCUMENT AND EXHIBIT A ATTACHED HERETO, IT BECOMES A LEGALLY ENFORCEABLE AGREEMENT EFFECTIVE ON THE DATE SIGNED BY THE COMPANY.</div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br>
    </div>
    <table cellspacing="0" cellpadding="0" border="0" id="zb7cf6b6e075f48ac86044a26450b0da8" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

        <tr>
          <td style="width: 8%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
            <div style="text-align: justify;">Dated:</div>
          </td>
          <td style="width: 15%; vertical-align: top; border-bottom: 2px solid black; font-family: 'Times New Roman'; font-size: 10pt;">
            <div style="text-align: justify;">May 25, 2022</div>
          </td>
          <td style="width: 20%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>
          <td style="width: 27%; vertical-align: top; border-bottom: 2px solid black; font-family: 'Times New Roman'; font-size: 10pt;">
            <div style="text-align: justify; font-style: italic;">/s/ Howard Federoff</div>
          </td>
          <td style="width: 30%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 8%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>
          <td style="vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;" colspan="2">&#160;</td>
          <td style="vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;" colspan="2">
            <div style="text-align: justify; font-weight: bold;">HOWARD FEDEROFF</div>
          </td>
        </tr>
        <tr>
          <td style="width: 8%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>
          <td style="vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;" colspan="2">&#160;</td>
          <td style="vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;" colspan="2">&#160;</td>
        </tr>
        <tr>
          <td style="width: 8%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
            <div style="text-align: justify;">Dated:</div>
          </td>
          <td style="width: 15%; vertical-align: top; border-bottom: 2px solid black; font-family: 'Times New Roman'; font-size: 10pt;">
            <div style="text-align: justify;">May 25, 2022</div>
          </td>
          <td style="width: 20%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>
          <td style="vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;" colspan="2">
            <div style="text-align: justify; font-weight: bold;">BROOKLYN IMMUNOTHERAPEUTICS, INC.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 8%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>
          <td style="vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;" colspan="2">&#160;</td>
          <td style="vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;" colspan="2">&#160;</td>
        </tr>
        <tr>
          <td style="width: 8%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>
          <td style="vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;" colspan="2">&#160;</td>
          <td style="width: 27%; vertical-align: top; border-bottom: 2px solid black; font-family: 'Times New Roman'; font-size: 10pt;">
            <div style="text-align: justify;">By: <font style="font-style: italic;">/s/ Sandra Gurrola</font></div>
          </td>
          <td style="width: 30%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 8%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>
          <td style="vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;" colspan="2">&#160;</td>
          <td style="vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;" colspan="2">
            <div style="text-align: justify;">Name: Sandra Gurrola</div>
          </td>
        </tr>
        <tr>
          <td style="width: 8%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>
          <td style="vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;" colspan="2">&#160;</td>
          <td style="vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;" colspan="2">
            <div style="text-align: justify;">Title: Vice President of Finance</div>
          </td>
        </tr>

    </table>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br>
    </div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;">
      <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"> </div>
    <br>
  </div>
  <font style="font-family: 'Times New Roman'; font-size: 10pt;"> </font>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>4
<FILENAME>brhc10038309_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, Inc
         Document created using EDGARfilings PROfile 8.2.0.0
         Copyright 1995 - 2022 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <font style="font-family: 'Times New Roman'; font-size: 10pt;"> </font>
  <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
  <div>
    <div style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Exhibit 99.1</div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;"><img src="image1.jpg"></div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br>
    </div>
    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Brooklyn ImmunoTherapeutics Announces Changes to Executive Management:</div>
    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Matt Angel, Ph.D. Appointed Interim Chief Executive Officer and President,</div>
    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Andrew Jackson Appointed Chief Financial Officer</div>
    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Postpones 2022 Annual Meeting</div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">SAN DIEGO, MAY 31, 2022 (GLOBE NEWSWIRE) -- </font><font style="font-family: 'Times New Roman'; font-size: 10pt;">Brooklyn ImmunoTherapeutics, Inc<font style="color: rgb(0, 0, 0);">. (Nasdaq:BTX) (&#8220;Brooklyn&#8221; or the &#8220;Company&#8221;), a biopharmaceutical company focused on exploring the role that cytokine, gene
          editing, and cell therapy can have on the immune system for treating patients with cancer, blood disorders, and monogenic diseases, today announced the appointment of Matt Angel, Ph.D., Co-Founder, Chairman, and CEO of Factor Bioscience Inc., as
          Interim Chief Executive Officer and President.&#160; He will replace Howard J. Federoff, M.D., Ph.D., Chief Executive Officer and President, who departs to focus on building a new venture. The Company also announces the appointment of Andrew Jackson
          as Chief Financial Officer.</font></font></div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#8220;Matt&#8217;s deep experience in cell therapy product development was an important consideration in Brooklyn&#8217;s choice to license Factor&#8217;s RNA development
      platform, which is the foundation of our current development programs.&#160; Therefore, it is only fitting that he take on the mantel to lead Brooklyn,&#8221; said Charles Cherington, Brooklyn&#8217;s Chairman of the Board. &#8220;On behalf of the Board of Directors, I
      would like to thank Howard for his service and many contributions to the Company. I am also delighted that Andrew Jackson has joined our team as Chief Financial Officer at such an exciting time for the company. His impressive track record in
      financing both commercial and clinical-stage biotech companies will be critical as the company enters its next phase of growth.&#8221;</div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#8220;I am excited for this opportunity to lead Brooklyn ImmunoTherapeutics and to help realize the full potential of the company,&#8221; said Dr. Matt Angel,
      Brooklyn&#8217;s Interim Chief Executive Officer and President. &#8220;I look forward to leveraging my experience as CEO of an mRNA-focused biotechnology company to help advance Brooklyn&#8217;s therapeutic platform.&#8221;</div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Dr. Angel is an experienced biotechnology entrepreneur and executive, having led Factor Bioscience Inc. as CEO since its founding in 2011. Dr. Angel
      is Co-Founder of the immuno-oncology company, Exacis Biotherapeutics, where he serves as Scientific Advisory Board Chair, and the cell therapy company, Novellus Therapeutics, which was acquired by Brooklyn in 2021. Dr. Angel has deep experience in
      cell therapy product development, intellectual property protection and licensing, contract negotiation, including collaboration and licensing agreements, and has raised more than $150 million through grants, equity financings, and M&amp;A. A pioneer
      in mRNA technology, Dr. Angel is a prolific inventor with more than 100 patents covering mRNA, nucleic acid delivery, gene editing, and cell reprogramming technologies. Dr. Angel received his Ph.D. from the Massachusetts Institute of Technology,
      where he studied immunology and synthetic RNA.</div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Mr. Jackson joins the Company from Ra Medical Systems, a medical device company focused on vascular diseases where he served as its Chief Financial
      Officer and Secretary and for a period, its Interim Chief Executive Officer. Mr. Jackson has held several senior financial positions, including Chief Financial Officer, at AltheaDx, Inc, a commercial stage molecular diagnostics company specializing
      in precision medicine and Celladon Corporation, a publicly-traded, clinical stage gene therapy company, as well as senior financial positions at Sapphire Energy, an industrial biotechnology company. Mr. Jackson received a MSBA in Finance in December
      2006 from San Diego State University and a BSB in Accounting in June 1992 from the University of Minnesota. Mr. Jackson is also a certified public accountant (inactive).</div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><u>Postponement of 2022 Annual Meeting</u></div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">In connection with Dr. Angel&#8217;s and Mr. Jackson&#8217;s appointments, together with the other events disclosed by the Company in its Current Report on Form
      8-K filed today with the Securities and Exchange Commission, the Board determined to postpone the Company&#8217;s 2022 Annual Meeting, currently scheduled for June 7, 2022, to a date to be determined. The Board will both determine the date for the Annual
      Meeting and establish a new record date for the Annual Meeting, and, based on this record date, the Company will deliver a new notice of the Annual Meeting to stockholders entitled to receive notice of the Annual Meeting.&#160; Additionally, the Company
      expects to file a new proxy statement on Schedule 14A in respect of the Annual Meeting.</div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">About Brooklyn ImmunoTherapeutics</div>
    <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Brooklyn is focused on exploring the role that cytokine, gene editing, and cell therapy can have in treating patients with cancer, blood disorders,
      and monogenic diseases.</div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">Brooklyn has multiple next-generation cell and gene-editing therapies
        in preclinical development for various indications including acute respiratory distress syndrome, solid tumor indications, as well as in vivo gene-editing therapies for rare genetic diseases. For more information about Brooklyn and its clinical
        programs, please visit </font><font style="font-family: 'Times New Roman'; font-size: 10pt;">www.BrooklynITx.com<font style="color: rgb(0, 0, 0);">.</font></font></div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br>
    </div>
    <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Forward-Looking Statements</div>
    <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E
      of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are any statements that are not statements of
      historical fact and may be identified by terminology such as &#8220;believe,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;possible,&#8221; &#8220;potential,&#8221; &#8220;project,&#8221; &#8220;will&#8221; or other similar words and the negatives of such words. Forward-looking statements are based on
      current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those stated or implied in any forward-looking statement as a result of various
      factors, including, but not limited to, uncertainties related to: (i) the evolution of Brooklyn&#8217;s business model into a platform company focused on cellular, gene editing and cytokine programs; (ii) Brooklyn&#8217;s ability to successfully,
      cost-effectively and efficiently develop its technology and products; (iii) Brooklyn&#8217;s ability to successfully commence clinical trials of any products on a timely basis or at all; (iv) Brooklyn&#8217;s ability to successfully fund and manage the growth of
      its development activities; (v) Brooklyn&#8217;s ability to obtain regulatory approvals of its products for commercialization; and (vi) uncertainties related to the impact of the COVID-19 pandemic on the business and financial condition of Brooklyn,
      including on the timing and cost of its clinical trials. You should not rely upon forward-looking statements as predictions of future events. The forward-looking statements made in this communication speak only as of the date on which they were made,
      and Brooklyn does not undertake any obligation to update the forward-looking statements contained herein to reflect events that occur or circumstances that exist after the date hereof, except as required by applicable law.&#160; Factors that may cause
      Brooklyn's actual results from those expressed or implied in forward-looking statements contained in this press release are more fully disclosed in Brooklyn&#8217;s periodic public filings with the U.S. Securities and Exchange Commission, particularly
      under the heading &#8220;Risk Factors&#8221; in Brooklyn&#8217;s Annual Report on Form 10-K for the year ended December 31, 2021.</div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br>
    </div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Investor Relations Contact:</div>
    <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Solebury Trout</div>
    <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">917-936-8430</div>
    <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">investors@brooklynitx.com</div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br>
    </div>
    <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Media Contact:</div>
    <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Michael V. Morabito, Ph.D.</div>
    <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Solebury Trout</div>
    <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">917-936-8430</div>
    <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">btx@soleburytrout.com</div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br>
    </div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;<br>
      <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
  </div>
  <font style="font-family: 'Times New Roman'; font-size: 10pt;"> </font>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>btx-20220509.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by EDGARfilings PROfile 8.0.0.0 Broadridge-->
<xs:schema targetNamespace="http://brooklynitx.com/20220509" elementFormDefault="qualified" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:btx="http://brooklynitx.com/20220509" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="btx-20220509_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="btx-20220509_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:roleType roleURI="http://brooklynitx.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000100 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/dei/2021" schemaLocation="https://xbrl.sec.gov/dei/2021/dei-2021.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/currency/2021" schemaLocation="https://xbrl.sec.gov/currency/2021/currency-2021.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/exch/2021" schemaLocation="https://xbrl.sec.gov/exch/2021/exch-2021.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/naics/2021" schemaLocation="https://xbrl.sec.gov/naics/2021/naics-2021.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/sic/2021" schemaLocation="https://xbrl.sec.gov/sic/2021/sic-2021.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/stpr/2021" schemaLocation="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd" />
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xs:import namespace="http://www.xbrl.org/2004/ref" schemaLocation="http://www.xbrl.org/2004/ref-2004-08-10.xsd" />
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xs:import namespace="http://fasb.org/us-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xs:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd" />
  <xs:import namespace="http://fasb.org/srt-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd" />
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>btx-20220509_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by EDGARfilings PROfile 8.0.0.0 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" xlink:title="CoverAbstract" />
    <link:label xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CoverAbstract_lbl" xml:lang="en-US" id="dei_CoverAbstract_lbl">Cover [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:title="label: CoverAbstract to dei_CoverAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentType_lbl" xml:lang="en-US" id="dei_DocumentType_lbl">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentType" xlink:to="dei_DocumentType_lbl" xlink:title="label: DocumentType to dei_DocumentType_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications" xlink:label="WrittenCommunications" xlink:title="WrittenCommunications" />
    <link:label xlink:type="resource" xlink:label="dei_WrittenCommunications_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_WrittenCommunications_lbl" xml:lang="en-US" id="dei_WrittenCommunications_lbl">Written Communications</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:title="label: WrittenCommunications to dei_WrittenCommunications_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial" xlink:label="SolicitingMaterial" xlink:title="SolicitingMaterial" />
    <link:label xlink:type="resource" xlink:label="dei_SolicitingMaterial_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_SolicitingMaterial_lbl" xml:lang="en-US" id="dei_SolicitingMaterial_lbl">Soliciting Material</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:title="label: SolicitingMaterial to dei_SolicitingMaterial_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer" xlink:label="PreCommencementTenderOffer" xlink:title="PreCommencementTenderOffer" />
    <link:label xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US" id="dei_PreCommencementTenderOffer_lbl">Pre-commencement Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:title="label: PreCommencementTenderOffer to dei_PreCommencementTenderOffer_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="PreCommencementIssuerTenderOffer" xlink:title="PreCommencementIssuerTenderOffer" />
    <link:label xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US" id="dei_PreCommencementIssuerTenderOffer_lbl">Pre-commencement Issuer Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:title="label: PreCommencementIssuerTenderOffer to dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:label xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_AmendmentFlag_lbl" xml:lang="en-US" id="dei_AmendmentFlag_lbl">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:title="label: AmendmentFlag to dei_AmendmentFlag_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" id="dei_DocumentFiscalYearFocus_lbl">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:title="label: DocumentFiscalYearFocus to dei_DocumentFiscalYearFocus_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" id="dei_DocumentFiscalPeriodFocus_lbl">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:title="label: DocumentFiscalPeriodFocus to dei_DocumentFiscalPeriodFocus_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" id="dei_DocumentPeriodEndDate_lbl">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:title="label: DocumentPeriodEndDate to dei_DocumentPeriodEndDate_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:label xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityRegistrantName_lbl" xml:lang="en-US" id="dei_EntityRegistrantName_lbl">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:title="label: EntityRegistrantName to dei_EntityRegistrantName_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:label xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" id="dei_EntityCentralIndexKey_lbl">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:title="label: EntityCentralIndexKey to dei_EntityCentralIndexKey_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:label="EntityFileNumber" xlink:title="EntityFileNumber" />
    <link:label xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityFileNumber_lbl" xml:lang="en-US" id="dei_EntityFileNumber_lbl">Entity File Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:title="label: EntityFileNumber to dei_EntityFileNumber_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:label="EntityTaxIdentificationNumber" xlink:title="EntityTaxIdentificationNumber" />
    <link:label xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" id="dei_EntityTaxIdentificationNumber_lbl">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:title="label: EntityTaxIdentificationNumber to dei_EntityTaxIdentificationNumber_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="EntityIncorporationStateCountryCode" xlink:title="EntityIncorporationStateCountryCode" />
    <link:label xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" id="dei_EntityIncorporationStateCountryCode_lbl">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:title="label: EntityIncorporationStateCountryCode to dei_EntityIncorporationStateCountryCode_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:label="EntityEmergingGrowthCompany" xlink:title="EntityEmergingGrowthCompany" />
    <link:label xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" id="dei_EntityEmergingGrowthCompany_lbl">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:title="label: EntityEmergingGrowthCompany to dei_EntityEmergingGrowthCompany_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:label="EntityAddressAddressLine1" xlink:title="EntityAddressAddressLine1" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" id="dei_EntityAddressAddressLine1_lbl">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:title="label: EntityAddressAddressLine1 to dei_EntityAddressAddressLine1_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2" xlink:label="EntityAddressAddressLine2" xlink:title="EntityAddressAddressLine2" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US" id="dei_EntityAddressAddressLine2_lbl">Entity Address, Address Line Two</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:title="label: EntityAddressAddressLine2 to dei_EntityAddressAddressLine2_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine3" xlink:label="EntityAddressAddressLine3" xlink:title="EntityAddressAddressLine3" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine3_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US" id="dei_EntityAddressAddressLine3_lbl">Entity Address, Address Line Three</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:title="label: EntityAddressAddressLine3 to dei_EntityAddressAddressLine3_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:label="EntityAddressCityOrTown" xlink:title="EntityAddressCityOrTown" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" id="dei_EntityAddressCityOrTown_lbl">Entity Address, City or Town</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:title="label: EntityAddressCityOrTown to dei_EntityAddressCityOrTown_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince" xlink:label="EntityAddressStateOrProvince" xlink:title="EntityAddressStateOrProvince" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" id="dei_EntityAddressStateOrProvince_lbl">Entity Address, State or Province</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:title="label: EntityAddressStateOrProvince to dei_EntityAddressStateOrProvince_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCountry" xlink:label="EntityAddressCountry" xlink:title="EntityAddressCountry" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressCountry_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressCountry_lbl" xml:lang="en-US" id="dei_EntityAddressCountry_lbl">Entity Address, Country</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:title="label: EntityAddressCountry to dei_EntityAddressCountry_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:label="EntityAddressPostalZipCode" xlink:title="EntityAddressPostalZipCode" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" id="dei_EntityAddressPostalZipCode_lbl">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:title="label: EntityAddressPostalZipCode to dei_EntityAddressPostalZipCode_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:label="CityAreaCode" xlink:title="CityAreaCode" />
    <link:label xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CityAreaCode_lbl" xml:lang="en-US" id="dei_CityAreaCode_lbl">City Area Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:title="label: CityAreaCode to dei_CityAreaCode_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:label="LocalPhoneNumber" xlink:title="LocalPhoneNumber" />
    <link:label xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_LocalPhoneNumber_lbl" xml:lang="en-US" id="dei_LocalPhoneNumber_lbl">Local Phone Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:title="label: LocalPhoneNumber to dei_LocalPhoneNumber_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle" xlink:label="Security12bTitle" xlink:title="Security12bTitle" />
    <link:label xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_Security12bTitle_lbl" xml:lang="en-US" id="dei_Security12bTitle_lbl">Title of 12(b) Security</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:title="label: Security12bTitle to dei_Security12bTitle_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_NoTradingSymbolFlag" xlink:label="NoTradingSymbolFlag" xlink:title="NoTradingSymbolFlag" />
    <link:label xlink:type="resource" xlink:label="dei_NoTradingSymbolFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US" id="dei_NoTradingSymbolFlag_lbl">No Trading Symbol Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:title="label: NoTradingSymbolFlag to dei_NoTradingSymbolFlag_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol" xlink:label="TradingSymbol" xlink:title="TradingSymbol" />
    <link:label xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_TradingSymbol_lbl" xml:lang="en-US" id="dei_TradingSymbol_lbl">Trading Symbol</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:title="label: TradingSymbol to dei_TradingSymbol_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName" xlink:label="SecurityExchangeName" xlink:title="SecurityExchangeName" />
    <link:label xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_SecurityExchangeName_lbl" xml:lang="en-US" id="dei_SecurityExchangeName_lbl">Security Exchange Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:title="label: SecurityExchangeName to dei_SecurityExchangeName_lbl" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>btx-20220509_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by EDGARfilings PROfile 8.0.0.0 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:roleRef roleURI="http://brooklynitx.com/role/DocumentAndEntityInformation" xlink:type="simple" xlink:href="btx-20220509.xsd#DocumentAndEntityInformation" />
  <link:presentationLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/DocumentAndEntityInformation">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" xlink:title="CoverAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentType" xlink:title="presentation: CoverAbstract to DocumentType" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="AmendmentFlag" xlink:title="presentation: CoverAbstract to AmendmentFlag" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentPeriodEndDate" xlink:title="presentation: CoverAbstract to DocumentPeriodEndDate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityRegistrantName" xlink:title="presentation: CoverAbstract to EntityRegistrantName" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="EntityIncorporationStateCountryCode" xlink:title="EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityIncorporationStateCountryCode" xlink:title="presentation: CoverAbstract to EntityIncorporationStateCountryCode" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:label="EntityFileNumber" xlink:title="EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityFileNumber" xlink:title="presentation: CoverAbstract to EntityFileNumber" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:label="EntityTaxIdentificationNumber" xlink:title="EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityTaxIdentificationNumber" xlink:title="presentation: CoverAbstract to EntityTaxIdentificationNumber" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:label="EntityAddressAddressLine1" xlink:title="EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine1" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine1" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2" xlink:label="EntityAddressAddressLine2" xlink:title="EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine2" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine2" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine3" xlink:label="EntityAddressAddressLine3" xlink:title="EntityAddressAddressLine3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine3" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine3" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:label="EntityAddressCityOrTown" xlink:title="EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressCityOrTown" xlink:title="presentation: CoverAbstract to EntityAddressCityOrTown" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince" xlink:label="EntityAddressStateOrProvince" xlink:title="EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressStateOrProvince" xlink:title="presentation: CoverAbstract to EntityAddressStateOrProvince" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCountry" xlink:label="EntityAddressCountry" xlink:title="EntityAddressCountry" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressCountry" xlink:title="presentation: CoverAbstract to EntityAddressCountry" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:label="EntityAddressPostalZipCode" xlink:title="EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressPostalZipCode" xlink:title="presentation: CoverAbstract to EntityAddressPostalZipCode" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:label="CityAreaCode" xlink:title="CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="CityAreaCode" xlink:title="presentation: CoverAbstract to CityAreaCode" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:label="LocalPhoneNumber" xlink:title="LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="LocalPhoneNumber" xlink:title="presentation: CoverAbstract to LocalPhoneNumber" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications" xlink:label="WrittenCommunications" xlink:title="WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="WrittenCommunications" xlink:title="presentation: CoverAbstract to WrittenCommunications" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial" xlink:label="SolicitingMaterial" xlink:title="SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="SolicitingMaterial" xlink:title="presentation: CoverAbstract to SolicitingMaterial" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer" xlink:label="PreCommencementTenderOffer" xlink:title="PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="PreCommencementTenderOffer" xlink:title="presentation: CoverAbstract to PreCommencementTenderOffer" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="PreCommencementIssuerTenderOffer" xlink:title="PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="PreCommencementIssuerTenderOffer" xlink:title="presentation: CoverAbstract to PreCommencementIssuerTenderOffer" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_NoTradingSymbolFlag" xlink:label="NoTradingSymbolFlag" xlink:title="NoTradingSymbolFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="NoTradingSymbolFlag" xlink:title="presentation: CoverAbstract to NoTradingSymbolFlag" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:label="EntityEmergingGrowthCompany" xlink:title="EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityEmergingGrowthCompany" xlink:title="presentation: CoverAbstract to EntityEmergingGrowthCompany" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentFiscalYearFocus" xlink:title="presentation: CoverAbstract to DocumentFiscalYearFocus" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentFiscalPeriodFocus" xlink:title="presentation: CoverAbstract to DocumentFiscalPeriodFocus" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityCentralIndexKey" xlink:title="presentation: CoverAbstract to EntityCentralIndexKey" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle" xlink:label="Security12bTitle" xlink:title="Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="Security12bTitle" xlink:title="presentation: CoverAbstract to Security12bTitle" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol" xlink:label="TradingSymbol" xlink:title="TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="TradingSymbol" xlink:title="presentation: CoverAbstract to TradingSymbol" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName" xlink:label="SecurityExchangeName" xlink:title="SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="SecurityExchangeName" xlink:title="presentation: CoverAbstract to SecurityExchangeName" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>image1.jpg
<TEXT>
begin 644 image1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" !  /X# 2(  A$! Q$!_\0
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M3G5G/25CA])^(7C[7+:'0](NKBYO7=I&FC0&9EXXSC"J/7WKU67QC?\ P_\
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MC-8SZ=\&Y;:\OIK^Y26#S+F;&Z1MXR>.@]!7 > #K$/P9\0WOAZ\FM+VSO\
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MWV2 #ED ^:1O1>P]3GL*Z8U.3!)K>QSRASXVS[GNGQ"%Q)X;>&TD,;SRI$S
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M MWJ4T]C+>"[1$ C<+MVDGO]:]'_ .&@[+_H7[K_ ,"%_P *[?\ X5/X*_Z
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:U4C&$-$CCP]"5.4ISW84445RG4%%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139842977648568">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>May 09, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">May  09,  2022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Brooklyn ImmunoTherapeutics, Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-11460<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">31-1103425<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">10355 Science Center Drive<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 150<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Diego<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92121<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">212<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">582-1199<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000748592<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.005 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">BTX<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>brhc10038309_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="btx-20220509.xsd" xlink:type="simple"/>
    <context id="c20220509to20220509">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
        </entity>
        <period>
            <startDate>2022-05-09</startDate>
            <endDate>2022-05-09</endDate>
        </period>
    </context>
    <dei:AmendmentFlag
      contextRef="c20220509to20220509"
      id="Fact_2101f6fe8e0a4ca1b162445f11f2124e">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="c20220509to20220509"
      id="Fact_a7f13b2fb43547c68edda33d2cea637d">0000748592</dei:EntityCentralIndexKey>
    <dei:DocumentType
      contextRef="c20220509to20220509"
      id="Fact_9541381f3e5044e1928bdf3aadd25573">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="c20220509to20220509"
      id="Fact_8f44890b52db416ea26adbf19a53f3d0">2022-05-09</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="c20220509to20220509"
      id="Fact_3ba92018f4e74a0f9ca50c9fddf4d99c">Brooklyn ImmunoTherapeutics, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="c20220509to20220509"
      id="Fact_8149dc346d2742cd95ef25b933806503">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="c20220509to20220509"
      id="Fact_eef9553a254a495dbd09e81da27720ab">001-11460</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="c20220509to20220509"
      id="Fact_82e70fdfd38f4529bb322e982aecf2a6">31-1103425</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="c20220509to20220509"
      id="Fact_65b0595fd12c4b3a82cc7838938cf3df">10355 Science Center Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="c20220509to20220509"
      id="Fact_b764089a33cd430082fc7dfe89965374">Suite 150</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="c20220509to20220509"
      id="Fact_7c2ca66e7ec9429d9ecac53bcc2fb202">San Diego</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="c20220509to20220509"
      id="Fact_5d7a34548b4a4f82b5eb8f46ec617f50">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="c20220509to20220509"
      id="Fact_b580a48429994e65b24f1407abc886a8">92121</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="c20220509to20220509"
      id="Fact_f39f70719f0243c98c0e5feced9b86d2">212</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="c20220509to20220509"
      id="Fact_5d73a04312fc4188bf7099f779c79423">582-1199</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="c20220509to20220509"
      id="Fact_d5389ed488ca40e383869de29fb59653">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="c20220509to20220509"
      id="Fact_30f9d8a7d5504141976b73fea8d43d70">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="c20220509to20220509"
      id="Fact_e4aa2395c73e49d283165c88d4e43bd8">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="c20220509to20220509"
      id="Fact_12531d3145254f398dce72f468bc9ae7">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="c20220509to20220509"
      id="Fact_8a1c9d7128624a659679ba07ed3de93e">Common Stock, par value $0.005 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="c20220509to20220509"
      id="Fact_3efaf9344c934859a35fab3e73b74f42">BTX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="c20220509to20220509"
      id="Fact_a04be28562dc4082904d7bb16eceac7d">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="c20220509to20220509"
      id="Fact_e8e07683774d4292ad647bd5ebbf3c9b">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>11
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MR(7KW!JPA&2KR"Q-"Z47L3 \$X6587X&4SV\0%BO*];K4UA!39M,FW+IG)'
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MPS ,0'_%T)XP!] AB#-E\18$^0%6H@_8$@6*19V_K]JE<9 +&7D]/!+<'FE
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M%S?W1:[-XPFNWPQP>'3^ 5!+ P04    " #..[]499!YDAD!  #/ P  $P
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MKP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ SCN_5)E<G",0!@
MG"<  !,              ( !S $  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"
M% ,4    " #..[]4_!AP&5D$  #\$   &               @($-"   >&PO
M=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ SCN_5)^@&_"Q @
MX@P   T              ( !G P  'AL+W-T>6QE<RYX;6Q02P$"% ,4
M" #..[]4EXJ[',     3 @  "P              @ %X#P  7W)E;',O+G)E
M;'-02P$"% ,4    " #..[]4'#AEZC\!   \ @  #P              @ %A
M$   >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ SCN_5"0>FZ*M    ^ $
M !H              ( !S1$  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS
M4$L! A0#%     @ SCN_5&60>9(9 0  SP,  !,              ( !LA(
J %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&      D "0 ^ @  _!,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="brhc10038309_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000100 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://brooklynitx.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="brhc10038309_8k.htm">brhc10038309_8k.htm</File>
    <File>brhc10038309_ex10-1.htm</File>
    <File>brhc10038309_ex10-2.htm</File>
    <File>brhc10038309_ex99-1.htm</File>
    <File>btx-20220509.xsd</File>
    <File>btx-20220509_lab.xml</File>
    <File>btx-20220509_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>16
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "brhc10038309_8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "brhc10038309_8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "btx-20220509_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "btx-20220509_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "btx-20220509.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2004/ref-2004-08-10.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/currency/2021/currency-2021.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd",
      "https://xbrl.sec.gov/exch/2021/exch-2021.xsd",
      "https://xbrl.sec.gov/naics/2021/naics-2021.xsd",
      "https://xbrl.sec.gov/sic/2021/sic-2021.xsd",
      "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd"
     ]
    }
   },
   "elementCount": 29,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 23,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "btx",
   "nsuri": "http://brooklynitx.com/20220509",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10038309_8k.htm",
      "contextRef": "c20220509to20220509",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "000100 - Document - Document and Entity Information",
     "role": "http://brooklynitx.com/role/DocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10038309_8k.htm",
      "contextRef": "c20220509to20220509",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://brooklynitx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://brooklynitx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://brooklynitx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://brooklynitx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://brooklynitx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://brooklynitx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://brooklynitx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://brooklynitx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://brooklynitx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://brooklynitx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://brooklynitx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://brooklynitx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://brooklynitx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://brooklynitx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://brooklynitx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://brooklynitx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://brooklynitx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://brooklynitx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://brooklynitx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://brooklynitx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://brooklynitx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://brooklynitx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://brooklynitx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://brooklynitx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://brooklynitx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://brooklynitx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://brooklynitx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://brooklynitx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>17
<FILENAME>0001140361-22-021148-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001140361-22-021148-xbrl.zip
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MG']Y%R,;^'L<AB+=TRL*XV*6<%A-FJ4"'GD5WQSBVD4N/]+=]!%N^ 1 S^.
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ME$F9BY0A4<]Q'4H#@=7!PO&$?#CAN"H,J[R/#;#T@-H;D=\E_VUY"[R;"$6
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MN&^G;TL\_SE"7:[7&]G?WJ[<S70(#&3@K_?L;8U*(QQ[Q4&>8_I-,07)U T
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MQ\5<; WKM?HABAOU>=R4YJ<=S0!G#'%_257!##.R:NHRO(2YL#,.ZJL9_Z8
M!SW;YJD[^U-*,$Q"]*'CQ+CF:2'A$O-6MQBMUV-,,8&5K$ OK@?[,!8P-F ]
M*55AIR$?ME%BV@^Q ]!*RS@XD6!:(P-?" [OE&W1<(*)J(L&=CK#D?#=, +=
M;ETUI:CQV*5'.)T5X89S (3"!+0W/!@\ I=TE;Z]4.,#2>#HUA)8__O0G<=.
M,,I/5&/H.[DL>FTF#'?S=<"-2R9XR6V&P1[J+H3#G3@.X!3UR$9X.+C,>M7_
MY@@$^P5XZR:5![8#SH%4NL208/MCBDO9EV-TJ3OPXHH3M0TK!/P0_C]&OT&X
M34SB@A,<+%M .:3EC#,<#A)%%PFU#5PO.+\858=3R^D1F[ZH'';&3RPL,KI%
M=KH4@\N:?*DS_:"QA.T;8@F#=@/N?I)7M-Z/L84%.<;F]9L0E.Y9F(&\1LWZ
M,MBO^'#*\@W<AFX^JY5$MEIY'GKQ4 P4@W:B%RJ56E,L.<\)N$<PLTGPMFC*
MM9\;!/F!,D@G-4(1\<97*#KB(H-G5,'*?VUO[HPV-C961_@N4C0]F(H^ZYPC
MA?BM$AX65-$TB<%L&)&! L_(BX!2C4%&8H%<A;S.* .:@QF5U]/LNL_J47-T
MX8<RN4R3*YB*Y\2R4>!6XDT1EK$.D]N-.* L:9TXBX/S^U;/@WF%CD1B[%UZ
ME%;W3Q<^UNUM 4N(6;\RD0NT4'0L>]:]*S]PXV]W^H,>L.]C 'QQ 'SK,0"^
M5.W -^8*MZ5VD3<5R^LW"2PLY=Q(SH%4 4<I+(-KF+T N_LBRS#+%$5E73!<
MB')51@)'836%A8-W! CI%OB%$M<S,H.:.<?R:MC<A$POM.:N4<!%% />WOAA
MM3_)IB5D,\=48C1-0=C.Q(8C_1'SZ"0VXEM"_,YJ'3P;\+IZ?N/FBN^B*1#^
MF=[6 FMX%B-*5?-A^&AG[&X9%-A</9 SC;QZ=@S&EW*0S=L(>@'BM00S>ZMA
M&LNVL39Y'Y:P()L[9EYT#AB\9<QW/7OZM<5T5[B8//24-RE&_48YSU#-'//@
M&&(WR'.;508? ^/0B BYZDLA&VB:#(Y>-<( *"U]6KD\/<8J>E;?IN!C+QV=
ML^/JDM\#H'5_@KAX(^O/J]\9'Z/E0<):X;@H^>\6@[X'1@2-!%_7:Q+0<XLY
M9E&:',$\7<- ;^-MCTC+%@AC%& FW%XF$X2F]R5.U%%X +-!1\^L_3"X&FA:
M$F[6+L6\%.RD 2;DI+8(E0 JJ)790:>N(^Y<,-9'<7Q]#^@V\7'/6-IC="K<
M+1^N,PC:6:1\0'L<_:O! ZCWDW1)WPI],P[3YL;>@^C>]/9AZ),^5% O<AL_
MYAW0N(E8IUT@E)*CDCX@Y\/^V>'^_Q><U47T"87W)_CE::.OTL[S9R17MU=[
M53D]F:1'D/#&LLY&W*6+(+9<'T0\P2VNZ*TKG=*5>V5N?\(!M;.7WUQ,[<'.
MTW('BHP"XQWSWO&1T+XQQL76V%S)B_Q?#:::,5#/VU3,2?+RU^Z=7S_AI_5M
MECLZSY]OC_8V-G# 92<BWGN8V/H!M<+?P7**,DHQ4U>FSMC2+Y?52'"Z',K+
M"JIIM]\(Y5E+O-X@^'B16!F?:_^ZY\V7F/\+.0AY!6?C>FU"U7)BQ<I;90EH
M:9*8]>[8 @TG:8D/ 4,<?HW![R&H(^KIS:?/GIO?E\DL3,E\'WY!@E5M$FZX
M^1W\37+=2$;AMY7E1H:W,Q26-+ ZE7SU%%ROBZG,(4LN<3UQ)7$J\1?4MU_C
MQM]TY2GQP9'@7@3J\"T8<UJS"F>)!?VTCCO9N"C@T7"C9_%AMT#$:MUM]WG[
M-6GEBJ-@^]&XK=.Z(92KD2<+-)@I>/Q]=9^G\L@\I]L_H8N!.(!</]Z@)+SC
M#!_PW!4O[=.WK-.4))[V5K_C(WQY=TQ:?^3 ,SU<"87*_LDGTARE*@G8+,P[
MF1XZ\[FW>UR*3 "0KAL]X!:Q$NUU(+6K_LUM, 68[EE4 /L;+[>]6*-(4NKH
M,RYB(B&EX]SB'4QFSDL)('HL-=655 RW*/A?E'Q4TMD8ZS_Z4.&2ZEZ(Q:9W
M$2++Q(,0.P'./BI"JNLT>><1#A!V&91E+&PY6.-F\WN)3!:/8E.6KL:^%15:
M)NO1)PB];/0UJ6 ZP5V\Q2M5-B!K.@JFQ55RR?D4J=R4<%MX&:99*%?/+1XN
M#(4@.)$]8A('!/Y9@@%617;>!O>4EHG%!OJ80"SL=)"!]8X<  ,"+EIP6<![
MP1811 J%=BJ[4_9]^ ,.O]A3($4$*HB"UD3=6\5@'M3ZMBQO2X#0HN$$28R,
M$[?\_7'0G,B98N^(6HL'D\N=!;H!T6,&%!45E[-A/(PCI5NXRY.$2I&I&#07
MO@:U#C:F6M0(@^"=AZ?\%^6X7(A(((RKM-*3#,U]@S'#_\#<YP6\B*Z)BX2:
M*Q!E844)YW%2(_35;)D\B/YN5Y3Q$6B6PL^;$@XH+!*N:Y;D%_6T>SK"K'*Z
MX;]V-IZ2[4H/Y56!EQ=12H$>OTQ/R*PZRSLKQDAH%2=X_6CN4R2IH'1YSA:%
MF]R\*6'N2>65XO2I_/?\U(_3(N>'_HP//38/_4@';/VA660>2S66RU0]>\Q4
M??U,5;*<(>'LB8^8C\ G84T 72KZR<]PES""RP;&#8*8<AJD)\'F7S*9KS2I
M@,#(8%R@?+7<0MH:8]>B+)EDR6?ZBS\49]=V8A!H2!BE]!4P9 \"P.ZM;^TQ
M!I,<C"J.T]/Z&$TQE4WN:EK2"*U=9DU7(<(B6-E=Y4=-LB*D$()Y%H62O"B_
M]6Y_R1LT\KM?P:K"*"PQ0$)*"W?>3Q2@Y^O]P*C=6?@YG34S4N(XKLV-U9X7
MN+*8L1P1M!0HLU@E\]"Q1>CZQ<K87,8_4KY1%EZM!R>4O83UW=Q8@]=TW@M#
MGBN;J<3 CB%O8$1>8M9;4E<7*2XNV:+]B\MEK!6J/72Q<3W_&#0>S!W9=UY]
MY'/?P5-8;MX[V/Z<_@1RV!33MZUXBD+X&_:->8WW%_:3^\(2WJ(;EP1OA-"$
MH=HM =(7<.SS+<6_5X#HQ5I#H1,RQ:GBG*8+^%%)MC.,PNRN5-BUC$6[]V5Q
M48:S2F&[\^(J0-A^.J%+YBK C9EM@Z\MYX,2FN*;X,C!PQEGR.G4)G'B2I<\
MMM*6B2%LAMH.BH)B)3T019Q; !_2[XUB,(9B"J!<U3PGED=M)+FZ!(MBF[(!
M%.31:CB44AO6P.#M48FZE.2+LN!/]JE90X1!%6@Q7(01%S:,W$9X10OD^%YA
M^D' ^CA-/;0 _CL-6P/$#['HY'H.?R,<1P8L'\N![S.(=''[3"G(@%/M18L(
M^+5%@<BU^]K;1EUIP@4Z]#+B,S_\82,*-!S#.Z\.^N(.Z4MRRGE/Y3F>^=<*
M4X JSQ%7])E./=D+3LVJT[KDPQQ,7#_RE:N [,P6XZOFD2888F4@\3SF2OXA
M*J=DC"I;:[&'!6+A9/^:>M 8\W1F1./PF%#K\2%?=*:>O%95E4PSW0FK>/:)
MVJHL!=LH%L,)8U5R89GJ@9=++N[71W+< <N^<U<L^[FKP5D?=H67&A8B9A?O
MGP;4#O#G?FTCY=Z(=[6@7BRO75A&043+3=+*;E'9$XJ2:3IO%WF!ZFC!+E3Q
MBI1@,RF)D)5P]%;76H6?\ FBD<BO\+]H+K3^TCCAI+G83W[,"\PP7<D=30N*
MD.&'EIJBR"N4*7@C?T*PW2FSKZS$<"G)FD#0WVJG% A&[.;?-L6M(X42P:63
MKGVCL"B=02=U-O7U7,MV&KM-@\=20:"69Z2G@-+? /;@8QJ,JO/:65@AAN#:
M]^2D5-U\WW#1A%%48M(<:P<:]DP_GI_XI4L]KBJ""ZM:I=B1F\]2RG2]CI&(
M6%^J3LB'L3^+>Y(=-B=BLQ[Z\)M:6*M5-);0P$R7+*OH#=>WXC/7I@C_<I6M
M :,M'/K [KAUF]G>8G]M*!!C#/J6 4J4B6!S&P;LSNVA(W-O4,V^'((31W#7
MH7$X[JOA<M>P6G@/;WOY6O<-']TS1FOY?RCRM8/C ZUT_ PKY@46_)Y]%W=@
MJ5 GJ:(R'9LQC@8M-7(G1MJ7,&RDIDAT@,J*0,?I%\>8/0;J.5"__1BHOX=9
M]/5PK?Z_[X'W=/+(%W;$!L?RK(@X0BZ OMSF;:T*UP6^G'GM@0-\1H+2RAI#
M4O0+[MS^*@5O!0@$RH++_%%,+"X^P; ,EZ]([0M#TU?0Z2.#X0H.$N82U$-A
MZ+."J-V)OBYW!2^;2Q6\#+S3N(8Y>V:K2E(*C$_0>WU"<!O\QS>K-$SB.9)Q
M*@6#X6WA(Z$AV(]1/":MU)RPV/(Z6-G96 W@Q&$&OY\H:!'+SQ 5N0AUQS3K
MMDT7,"XHNT&\9\,XPY1I76#N!]X!B%-03\WP"0@;.&)PB! K(JP@(RF?IDA=
M#Y>(*?7)9/^0:(,H::ZFA6@ZQ^AC@W5J(!SV@N]50E/EK-<P.&!O%UM5P 4J
M"Y"_\):50STK9453[+_#>>FLFJI+BF[JW?E4.Q/3]/AH!P+MHKU2V!2:0UY(
MK(!J8YUZ9UIL,CL4K%!;*TV.E;1P73]KJBH,M57&L6EQ#6/("&2FF/@>HD]"
MRA@LN!0[";'2Y"TY3(PR5%"N8) Q_8R'^_G&JJTIP3>F>4K$MLEGLL?Y/+MY
M<H^'E6N?,FH2IAEY45$CK1YZ!F87 V>AET,&!/_"JKF59V9$[F"H<BD<BIN_
MK-;]VZO@N <(18\G_7,MX>#$UZW9#DY2T9AH*A#WWKXR,;UM?AJ-><U0FW#9
MF'(LX&Z.S)KF8!3CFK[HKFG;LZ,]5N.A>!\:#_VGJ$5#1;]WR]""U'K?;-GN
MZ\%;9%PV8)6>+@:RL1W9X*M7"NE/I%>,2@+T.$=;&UN;P;%#SC+P]M@B,D&.
MWUCN_0>HDQJOWLYV6C:TW8H<V8N!3E$('C]%D+YB$=4=DOQL??ZNQF:PK\)C
M\4(2&2UN_/#;C=!0VH"N.^S#RY8)M+%XJ+GH\.:HFWMW-_[6H3T&^S5UX #2
MM$XDD@IA;@C'JH2),7C2BGNLSU,GV432?9>&T@O%"!LS;NH.L2I;P()+O5-
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M/R[EDRJ$:B)VL*/)1:>0DQ<^)5 RV7$KO:@O9A<QS"E$^;DZ\J,L][+%Z53
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M3#_ESH5<6R^\4YWB%CL4FP6D9VG(KGFX>2YG  B/;Q,)"D%J69SPD6;^M>6
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M8YN(8!TTY&';\]P1V:U,M$IMM+*.7E32Y$M-[?'()5N+,KT@M80!#C;#*;B
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M6[0H*6O&2O4W"_4A0Q'<0L94@8D0&\DR /3Q_6)\6D]E'%$CP3:7:<9A3AP
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M&H\?W:4D:!8QV&J&- #3+$0@22.F6R96<$VFWBT$D5L*)9&LKV'E1J_;2HQ
ME$,5UU(P)(%!TL5>VSWAQ9Q1!3*/>G#C!#?HY"[O-UG?^]K7[AV81?".I7]4
M;$AL>E[8XDTQM#X87T84*7U\COQZC32%0-R=)$.O]8?H!>)AT00P=%%-P;9?
M0U.;FFV76#[D(JXWC8V'U$I#F?!2P:FH[G9[%9:^?B&Z(U P.B+GP#JVIISA
MJ=<N5.(B) M/A+JRBR\EQXKYG/!RZ%'"T@BK*FD;#D.2/G-12*N#1D)&FW(P
M%F](I3@>K;.J#H6&4%*M>0\Y4I';V#"\#7$]"I2Z<(+?;7GP_9@0VHU'%@1"
MM:T8XI5*^2N(TH#3P";-0@E@KICF DI"86D)^Y\N5]F=?"I=ML<4CXX]'L/=
MIIEQST1QP% %?09FVS6RY2!SRY>U?!X]X)8'O//H 7]]2I7[,>;_VN-5@!LX
M&R-MGH&-J1BEK8/QC!^LDJ.F:U:U(:!577"T #B+8K2=KCWP73@I1!H<0]EY
MM_]JYW#YB307S<,^Z$S%^3)8V5R5$+$\/X$MLLY9:QCL"9M&<SWOUMDAK'P
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MI"HRHBA\S+D/_WNX)'?6"+\9(:8#Q1>,>% P=BJA"2+^2@%"HXG"$&W7"'F
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M&ARB:VGR-DQ+]3$=C(V#GPON? /?Y0/M6A:J<$)DZO>EEM"45=CM)(PV;Y/
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M8N,) $+&M)NOS-%6Q\IA:74J7U_(UH55U63F$*T=OKB0F=D6=TIFLT2V*IB
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MEL45LM1-RG"6!%06GERD$1=.K($E)B4-DS!"R"N5U0I!P=J,VNR^"I*\0@U
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M N^F*UM(7$ 96.X7#6DRCT_C8<7N(W+HVT4._9^UM8^G)TAKZ"KW3N'FU#_
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M<&53MK:R:@?5A(SO=L+?/9WM63;JT9.M^ >>VR=.&3R,^S[(UA2?=]M-UKE
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MSYJ:3JL[=%K-UHI5E>&70H:2+5<_9O%-))[$!2YYK"C4#E3RC6VW>X77:GW
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M6%1><,F_C28%J_2T#4>>"L3?[U$;5>;]6IK^?A7QCO:3!P;7=DQN?+70W4
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M7&2JW;:K$TIL?1[TIA"UN=J%CMIS1+D",1R5%R+"<QV4=PK'-%H0A<<*+#:
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M\]W0#K#!QGY]:6V=E^&4+[K+UB,2F6FFMA?^FW1:7E'"-(U!].RDEC1Q55[
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M&?#1)PG-RA_W5WFW+3"?[J_R6DMT/GVJ/U'<>TA_8\D?PI^1_@]02P,$%
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M+*W%%3OBW_Q;-(7Y-^7._@=02P,$%     @ SCN_5-!30G?I!0  ]#X  !0
M  !B='@M,C R,C U,#E?<')E+GAM;-5;;6_B.!#^?M+]AQS[&<++[=Y2E5UQ
M]$5HNRUJ.=W+EU-(#%B;Q,@Q!?[]V<'FL.,D9FE74U5J:>;Q>&:>QTD\=2\_
M;Y/8>T8TPR0=-#JM=L-#:4@BG"X&C776#+(0X\;G3S__=/E+LWF+4D0#AB)O
MMO.NKVZ'CW,<<VCF31X?^$?D?6RUQ9?W.R5!1'&T0,VF&,Q1WR[$MUF0(8]/
MFF87VPP/&DO&5A>^O]EL6IM>B]"%WVVW._Y?7^^>PB5*@B9.,Q:D(6IX''^1
MY1?O2!BP/.*CX=L9C96#GG^8JQ0A?FLJ6%-<:G:ZS5ZGM<VBA@Q1F!TF4?!M
M 2]SZO3[?3^W'J#<$:YP?4B;5\_S]O6C)$:/:.Z)GW\\CDM']WV!\%/$[H(9
MBOF4^7"V6Z%!(\/)*D;JVI*BN=U/3.G!C:A.7U2G\T%4Y]W_GOUSPEL(*4T)
M"^*7B3/W5XRU,,WY0=^_5&FK0KY_R2KS)8Y^0)6/ICD_Z FBF$37:?3Z@9M3
MO53P3RR@/T JQ<G.3^#UHSXAU!DEY%N\2S';MD*2[+U?D7"=H)0-4\X<PVPW
M3N>$)OFCH3[P&=ORN+K=]OMV/X^JVMUQE"N*,@[,+7?\@C87VC*41BA2LXE0
MS\@CGU9-')-0FRL6#T)"BXQD?*Z<C@R%K05Y]B.$.<7=CO@@TLX?<^_X+_^.
M"'_^#V<9HT'(E*=84#-H6&T\0I&18?-?/5!5IBGW:,1I,\DP=9,>Y3&/0ZI'
M'-!0>>(?-1*+3VN)\%<!Y?Z:X1+'!_[GE"1EE225H1^'=^%I'CQ&/'TDH1&B
M@T9;O,+Q@7-$J5QA%7'G0<?'R_ U"1SR:",1\4T<+ P&K399!\,&C\.JX&M(
M-(9*%CN 652R.SPRK_B]O&0]6C'&PC0P\-AU2<9QJ1HN)-M=P&SO'TB/:(%%
M-BF[#Q*3["J(+(\= H]JAU1JF+9[D$3WP!,]YIM_NB(T3X^_3S(T(NN4T=V(
M1';>G49H,J@9 545IR3J))(:AU(SOX+7S V.T?TZF2%J%4C1K*GAV R5^M(4
MG'@^'BU)?0^>U&FP'4<\-3S'^UY;!<,U6(WN4BQ4[MV2<Q)"J2NIB@_@53&,
M(IYH)G_PK2_J6!51@=/48,5!54)]4DXJL+J1"OCM#2J@ZZB KJ,"NF]) 692
MWZF [D$!']^@ GJ."N@Y*J#WEA1@)O6="N@=%-!_*PH8\8\/=$HV:17_192-
M_6,4<.Y+$SJ%^6,GJN<#N76G!9_O51[HA))GO/_+;"G[)5";! I0X#JH3NT4
M,10\*45 ;@/J<MYO7"OO SK$>A-0$.#,VU,Y:?DK#XII^"U &?F$9"R(_\&K
MTH90%=#&N@$$SGU56J<HP/"C= "Y0RB>64.* @OS-I/Z,Z%F@L=N1>@U?.HC
M%8.0^W7BW%0\69+4WJ\K,\MR%,WPV*Q)H8;1XFC%*N2&W9\4,X;2$4F2=2H[
M2YE!;25&%J<$ X]DEV1JF"YQH>B&W(E[(C$.,</IXBM_;:0XB VNRP&R-C8
M/)9KTZBAV#9>\0NYSS:A2,@2\9U ?KI#'":B#_-YX79=#Y2%J@+"X]TYK1K^
MJ_PH'4#NMAGQC[-LC:BS&DKA=DU8X."549?B:?JP>%,J@=R1NR=3&HCC^D^[
M9$9BR\FJ"H0LE!4!C_[Z1&H8MSI09W#@=]^N$T07//I;2C9LR;6["E)[RZ42
MJ>W!2Y#PR'=/S&D77N)(B0%RXTV=);O!&=^M_(T">L.OF"_\-2CC#%X!!4\
M;@DYGL,K.%'$0^[#Z<'OCQ+64V_!6<G7<-#I+T_J) %H;I0$(+?@]C>O$4^
M!O&8OZILOR#[(Z $H]W\"QAXM+LDXW3#+[A0=$/NUSVA<$UY\)WN;"IR-3?Z
M)6:US2^8X?%;DT+=%K\P6K$*N5^GO80:E%IMLAB&#1Z95<'7,&D,532"[L-)
M\5UOPV60+I#E9'P5Q%BD.@0>MPZI."Y6W8-B^MR.W*5?*-4=OR#^]WQO$=_$
M_VI_^@]02P$"% ,4    " #..[]4K"L>7B J  #^^@  $P
M@ $     8G)H8S$P,#,X,S Y7SAK+FAT;5!+ 0(4 Q0    ( ,X[OU3I(GQK
MSF4  +0& @ 7              "  5$J  !B<FAC,3 P,S@S,#E?97@Q,"TQ
M+FAT;5!+ 0(4 Q0    ( ,X[OU3.=:Q"I"(  )#"   7              "
M 520  !B<FAC,3 P,S@S,#E?97@Q,"TR+FAT;5!+ 0(4 Q0    ( ,X[OU23
MOFDXM0\  $\Z   7              "  2VS  !B<FAC,3 P,S@S,#E?97@Y
M.2TQ+FAT;5!+ 0(4 Q0    ( ,X[OU3Q/^"16 ,  'D/   0
M  "  1?#  !B='@M,C R,C U,#DN>'-D4$L! A0#%     @ SCN_5/.$* 6!
M"   <E@  !0              ( !G<8  &)T>"TR,#(R,#4P.5]L86(N>&UL
M4$L! A0#%     @ SCN_5-!30G?I!0  ]#X  !0              ( !4,\
K &)T>"TR,#(R,#4P.5]P<F4N>&UL4$L%!@     '  < T@$  &O5      $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
